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INTRODUCTION: Gene therapy can be currently performed by viral or non-viral 
vectors. Although viral ones have already come to a clinical translation, concerns remain 
about both safety and the industrial applicability of this system. 
We therefore started the study of a transposon-based gene transfer system. We used 
nanoparticles (NPs) as vector to carry the transposon within the blood stream, then in cells. 
These had to be able to hold large plasmids, such as transposon. The NPs must then be able 
to reach the tissue most affected by the genetic disorder. Coating the NPs with specific 
peptides, they acquire the ability to accumulate in the target tissue, in our case the Central 
Nervous System (CNS) penetrating the blood-brain barrier (BBB). We started to develop a 
non-viral gene therapy approach in order to treat a neurological disease, globoid cell 
leukodystrophy in (GLD), an inherited, rapidly fatal disorder affecting myelin. 
METHODS: We tested the ability of a transposon-based system called Sleeping Beauty 
(SB), to convey the luciferase marker gene in the control cells. Then we modified the 
transposon cloning the GALC codifying sequence and we tested its ability to integrated the 
gene of interest in the cellular genome. 
We then verified the ability of NPS of chitosan to contain large plasmids. We then 
verified the quality (size, shape) of the NPS obtained and the ability to go into the cells. 
Lastly, we verified the ability of a heptameric synthetic glycopeptide, of opioid origin, 
g7, to convey inside the CNS NPs of Poly Lactic-Co-Glycolic Acid (PLGA). We injected 
PLGA NPs coated with g7 in tail vein’s Balb/c mice and followed through optical imaging 
their distribution. 
RESULTS: We verified the high SB transduction efficiency on control cells by their 
expression of luciferase marker gene. We then assessed the copies number of the integrated 
gene. We demonstrated the high transduction efficiency of the transgene within the 
genome of fibroblasts grown from biopsies of patients with GLD. We assessed the quality 
and features of chitosan-SB NPs. We could observe that g7 coated PLGA NPs accumulate 
in the CNS 10 minutes after infusion, with accumulation even and up to 2 hours. 
DISCUSSION: SB demonstrated high efficiency in stable transduction of control cells. 
So we thought to encapsulate SB in chitosan NPs. These have proven to be highly efficient 
in stably transducing deficient fibroblasts. We can confirm that g7 is today the best way to 
address the NPs to the CNS. 
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CONCLUSIONS: Future studies will test the ability of g7 to coat the NPs of chitosan, 
verify its efficiency in conveying the chitosan NPs to the CNS as well as they did for 
PLGA NPs. Finally, by cloning into SB the gene whose mutation causes GLD, can be 
assessed the therapeutic efficacy of the system in the mouse model of the disease. 
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2 Introduction 
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2.1 Transposable elements 
Transposable elements (TE) were discovered by McClintok during the analysis of 
maize’s unstable mutations in the 1940s [1]. The TE biological value is confirmed from the 
evidence that they are highly conserved among taxonomic groups, for example the 45% of 
the human genome is made of transposable elements [2]. The movable genetic elements 
are divided in two classes in respect of the transposition mechanism. The class I, or retro-
transposons, use a “copy and paste” mechanism, in which the TE is firstly transcribed from 
DNA to RNA and then the RNA is reverse transcribed to DNA. The copied DNA is 
inserted into the genome. Whereas the class II, or DNA transposons, are able to remove the 
gene of interest (GOI) from the donor site and integrate it into the target site using a “cut 
and paste” mechanism (Figure 1). Both of the two classes are divided in different groups 
[3, 4]. Class I is commonly grouped into three orders: TEs with long terminal repeats 
(LTRs); long interspersed nuclear elements (LINEs,LINE-1s or L1s); short interspersed 
nuclear elements. Class II is divided in families in correspondence of their TEs sequence. 
The families themselves are separated in Subclass I (Tc1/mariner, PIF/Harbinger, hAT, 
Mutator, Merlin, Transib, P, piggyBac and CACTA), and Subclass II (Helitron and 
Maverick) [6]. 
 
Figure 1: Transposable elements classification [7]. 
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2.1.1 Tc1/mariner superfamily 
The most extensive family in nature is the Tc1/mariner that is widely distributed within 
different taxa; only ten elements are naturally active and four Tc1/mariner transposons 
were reconstructed from inactive elements, such as Sleeping Beauty from salmonid-type 
fishes [5], Himar1 from the Horn Fly (Hematobia irritans) [10], Frog Prince from the frog 
Rana pipiens [11] and Hsmar1, incorporated into the SETMAR gene, from Homo sapiens 
[12]. The Tc1/mariner elements are length 1-5 Kb and the transposase protein is composed 
by 282-345 amino acids which are flanked by two Terminal Inverted Repeats (TIRs). 
Within this superfamily, the transposase protein’s sequence shows lots of differences even 
if all of them maintain the two characteristic domains: the motif that recognize and bind 
the TIRs (helix-turn-helix, HTH), the catalytic motif (three amino acids, DDD, for 
mariner-like elements or DDE for the Tc1-like elements) and the indispensable motif that 
is responsible for transposase transport through the nuclear membrane (Nuclear 
Localization Signal, NLS) [13]. 
2.1.2 Sleeping Beauty 
An ancient transposon element was brought back to life in 1997 from fish genomes and 
called Sleeping Beauty (SB), in analogy of the Grimm brothers’ fairy tale. It is a member 
of the Tc1/mariner superfamily, which is the most widespread DNA transposons in nature. 
Because of the accumulation of mutations in vertebrates these elements appear to be 
transcriptionally inactive [5]. The Sleeping Beauty structure is quite simple, and it consists 
in two-components: a gene-of-interest cloned between the terminal inverted repeats (IRs) 
of SB, which binds the transposase polypeptide, that is the enzymatic factor of 
transposition. SB transposase through a conservative cut-and-paste mechanism, excises the 
transposable element from its original location and then integrate it into a new location [6]. 
The two elements could be provided in trans form if are in two different elements or in cis 
form if the transposase and the transgene are located in the same construct (Figure 2), 
alternatively the enzymatic element could be provided as an mRNA or a protein [8]. 
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Figure 2: Schematics of Cis and Trans Sleeping Beauty plasmids. 
2.1.2.1 Transposase 
The transposase’s structure is highly conserved in all Tc1/mariner superfamily. 
Simplifying, the structure (Figure 3) is composed by different domains: the DNA-binding 
domain that is formed by two helix-turn-helix (HTH) motifs; the nuclear localization signal 
(NLS) flanked by phosphorylation target sites casein kinase II; these sites are very 
important because their phosphorylation regulate the transposition. The presence of the 
NLS sequence promotes the crossing of the nuclear membrane using the receptor-mediated 
transport machinery of the host cells [14]. The major domain is the catalytic one, which is 
responsible for the cleavage and joining reactions of the transposition event. Inside its C-
terminal there is a well-conserved triad of amino acids known as the aspartate-aspartate-
glutamate (DDE) which plays an essential role on the coordination of two cations 
necessary for the activity, indeed one of them stabilizes the transition state of the penta-
coordinated phosphate and the other one, like a general base, deprotonizes the nucleophile 
during transesterification and strand transfer [15]. 
12 | P a g .  
 
 
Figure 3: Schematic domain representation of SB transposase enzyme [16]. 
After the transposase discovery, researchers have done different amino acids 
modifications in order to generate transposase variants with no change in activity, reduced 
activity or a modest increase of transposition activity. The majority of the mutations have a 
neutral or negative effect on transposition activity. The mutations into the evolutionary 
conserved domains create an inactive transposase. The most active version is the SB100X 
that shows a 100-fold hyperactivity if compared to the originally resurrected transposase. 
The hyperactivity of SB100X could be explained by a particular combination of mutations 
that affect its folding features [17, 18]. 
2.1.2.2 Transposon 
The transposon vector contains the genetic element that has to be mobilized. The 
Inverted Terminal Repeats (IRs) are the distinctive part of the transposon ends, and they 
are composed of two functional parts: the 2 to 3 terminal base pair of the ends are the 
recombinationally active sequences involved in the cleavage and the strand transfer 
reactions; the other part is located in the IRs and it guarantees the sequence-specific 
positioning of the transposase on the transposon ends. The IRs length is 200 to 250 bp and 
each of them contains a pair of transposase-binding sites (short direct repeats DRs, 15 to 20 
bp) [19]. IR/DR is the organization of IRs that is present in numerous elements inside the 
Tc1 transposon family. Within the IR/DR group the spacing of about 200 bp between the 
outer and the inner DRs is highly preserved in all elements. The four DRs differ in length; 
indeed the outers are longer by two base pairs. In addition the four IRs show some 
differences, such as the left IR contains a sequence motif called “half-DR” (HDR). 
Moreover some experiments show that constructs modified with two right IRs have low 
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mobility, demonstrating that the left and the right have two different functions. 
Furthermore the multiple binding sites of the IR/DR elements control the timing and the 
specificity of the transposition reaction.[20] 
2.1.2.3 Cut and Paste mechanism 
The “cut and paste” (Figure 4) mechanism could be divided in four major steps: the 
binding of the transposase to its sites within the transposon IRs; formation of a synaptic 
complex; the excision from the donor site and the reintegration at a target site. Several 
studies have demonstrated that each transposition step is regulated by the host, indeed the 
regulation of SB transposition is mediated by transposon and host-encoded factors [21, 23]. 
 
Figure 4: Schematic representation of the cut-and-paste mechanism with some of the host factors which assist the 
transposition [22]. 
The early step is the formation of a nucleoprotein complex, in which the two ends of the 
elements are paired and held together by transposase subunits. The fundamental factors are 
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the four transposase binding sites, so the complete IRs; the transpositional enhancer HDR 
motif (a part of the left IR, it is important, but not essential) and tetramerization-competent 
transposase [24]. For efficient SB transposition in mammalian cells is required the high 
mobility group protein HMGB1, that is a non-histone, nuclear protein associated with 
eukaryotic chromatin and has the ability to bend the DNA [26]. In vivo studies suggested a 
ternary formation between the SB, the HMGB1 and the transposon DNA. It is supposed 
that HMGB1 promote the communication between the DNA motifs with the transposon. In 
fact HMGB1 is considered an important element for the formation and the stability of the 
synaptic complexes during the transposition, controlling the catalytic step [27]. 
The exposure of the 3’-OH groups of the transposon ends is the most important element 
for the excision of the donor site. Each cleavages is a transposon-catalyzed, Mg++-
dependent hydrolysis of phoshodiester bonds of DNA backbone [28]. In contrast to the 
other excision mechanism that involved a hairpin intermediate at the donor site, the 
mariner and the sleeping beauty transposases cleave at the transposon ends the two DNA 
strands by hydrolysis reactions. During the excision process the transposase leaves on the 
donor transposon three-nucleotide-long 3’-overhangs that are processed by the cellular 
DNA repair machinery creating on the transposon donor site a typical “footprint”. The 
NHEJ pathway is involved on the “footprint” generation and, for example, the molecules 
involved are Ku70 and DNA-PKcs [29] (Figure 5). In relation to that, a Kolacsek study 
suggested that there is a strong correlation between the excision step of DNA and the cell 
type. Moreover they have also demonstrated that high excision activity is not necessarily 
associated with the increasing of copy numbers, so the excision of DNA transposons is not 
always follows by integration. For example, working with the hyperactive variant 
(SB100X), the significant aspect that should be change to manipulate the copy numbers is 
the amount of the transposon instead of the transposase [30]. 
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Figure 5: Schematic representation of the "cut and paste" events. Left: the integration of the gene of interest. 
Right: the break donor site is repaired by the host DNA repair machinery (NHEJ pathway) and a small footprint 
is left behind at the site of excision [24]. 
The second step of the transposition reaction is the transesterification of the exposed 3’-
OH transposon tip to the target DNA molecule. Also in this process is involved the DNA 
repair mechanism that generate the typical duplication of the flanking element beside the 
target site (target site duplication, TSD). Given that SB transposition take place at TA 
dinucleotides, the integrated elements are always flanked by TA TDs. Despite the other 
transposons, at the DNA sequence level the SB shows a target selection, for example the 
bendability and the hydrogen bonding potential inside a palindromic AT-repeat consensus 
sequence [31]. For this reason studying the physical properties of a sequence it’s possible 
to predict the insertion sites [32]. In contrast with the specificity at the sequence level, at 
genomic level the integration is quite random and most of the insertions are located in 
introns [33, 34, 35]. The drawback of the sleeping beauty transposition is the auto-
integration in which the excised transposon molecule could reinsert into its own genome. 
This disruptive event is proportionally correlated with the increasing size of the 
transposon, because larger transposons show more potential target site [36]. 
In conclusion, the SB integration could be considered precise and fairly random, this is 
safer than retrovirus, HIV, or AAV integration events which have the tendency to integrate 
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into genes, especially for the AAV where the integration mechanism is also associated with 
a large deletion and chromosomal rearrangements (Table 1). 
 
Table 1:Main features of Sleeping Beauty system [9]. 
2.1.3 Sleeping Beauty applications 
Thanks to their low immunogenicity, low risk of insertional mutagenesis and the ability 
to integrate in stable way the gene of interest (GOI) inside the cellular genome for a long-
term expression, the transposon elements become the suitable tool for gene therapy [37]. 
Sleeping beauty was the first transposon element able to transfer gene in vertebrate cells 
with high efficiency becoming an interesting alternative to virus-based applications that are 
genotoxic and provoke immune response [38]. Evidence of the sleeping beauty potential as 
gene therapy tool, was demonstrated the first time in 2000 when researchers transfected a 
mouse model of hemophilia B with human blood coagulation factor IX [39]. Since then, a 
lot of preclinical studies was performed using the sleeping beauty system in different 
diseases models, for example to deliver coagulation factors [40, 41, 42], insulin [43], 
lysosomal enzymes [44] or to treat different types of cancer [45, 46, 47, 48,49]. In the 2008 
in the U.S.A. started the first human trial, in which they re-infused modified T cells in 
patients affected by CD19+ B-lymphoid malignancies [50]. Other clinical trials developed 
methods combining the gene therapy with the immune therapy demonstrating the stability 
and the safety of this therapeutic approach [51, 52, 53]. 
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2.2 Blood brain barrier 
The brain is surrounded by a thick blood vessels network that operate as a biological 
filter between the blood stream and the cerebral parenchyma. Its main purpose is to allow 
or not the molecular transfer from the blood to the cerebral parenchyma and the 
cerebrospinal fluid (CSF) in order to protect the nervous tissue. The blood brain barrier 
(BBB) guarantee the efficiency of the synaptic transmission maintaining the ionic 
environment stability and safeguarding the low gradient of excitatory neurotransmitters. 
Moreover it avoids the penetration of toxic molecules, such as metabolites and neurotoxins 
[54]. 
The BBB is composed by complex system of capillary endothelial cells which are 
surrounded and supported by other cell types, such as astrocytes (cells that link the BBB 
with the neurons), pericytes (that occupied the perivascular space and they maintained the 
vascular tone, stability, repair and angiogenesis and they modulate the astrocytes function), 
neurons and mast cells (Figure 6) [55]. The cerebral capillaries show different 
characteristics compared to the peripheral ones, because the cells form a continuum 
endothelium without the fenestrations and with a lower number of pinocytic cells. The 
peculiarity of this endothelium is the presence of the tight junctions that block the free 
diffusion of several molecules, indeed only the lipophilic molecules (oxygen, carbon 
dioxide, ethanol and steroid hormones), low molecular weight substances (< 500 Da) and 
molecules that use the receptor-mediated transport are able to cross the BBB [56]. Two 
components are critical in the tight junctions formation, the occludins which are proteins 
(60-65 KD) that regulated the tightness binding zona occludens protein-1 (ZO-1); and the 
claudin proteins that contributed to the BBB’s restriction of small ions. 
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Figure 6: The Blood Brain Barrier [57]. 
2.2.1 Mechanism to cross the blood brain barrier 
The influx and the efflux through the BBB is highly regulated (Figure 7), only the water 
soluble and the lipid soluble agents are able to cross the endothelium via the paracellular 
aqueous pathway and the trans-cellular through the lipid plasma membrane, respectively. 
For the other substances there are three pathways. The carrier mediated transport (CMT) is 
one of the transport used by the nutrients such as glucose, lactose and neutral amino acids 
which take advantage of membrane proteins located on the surface of the BBB, sometimes 
this molecular transfer is against electrical, chemical or electrochemical gradient (active 
transport). The highest expressed proteins is the glucose transporter (GLUT1) involved in 
the transport of essential polar molecule D-glucose, others are LAT 1 (Large neutral amino 
acid transporter), CAT 1 and CAT 3 (Cationic L-amino acid transporters) involved in the 
amino acids transport; CNT2 transporters involved in nucleosides transfer[87, 58, 59]. The 
receptor-mediated transport (RMT) is involved on the mechanism that allow large 
molecules to cross the BBB, for example insulin and transferrin. This type of transport is 
highly specific, indeed each receptor bind its specific ligand causing a vesicle formation, 
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and then both of them are internalized into the endothelium. In the presence of CNS 
disease the receptors expression change, so it is important to keep that in mind during 
nanoparticles design [60, 61]. The most commonly receptors involved in RMT are: the 
most well characterized TfR (transferrin receptor) that mediates the transcytosis of 
transferrin-bound iron through the brain capillary endothelial cell in humans [62]; insulin 
receptor that its distribution is altered in diabetes and obesity, so its use might disturb the 
insulin metabolism, so it should be used with caution [63]; the multi-functional and multi-
ligand lipoprotein receptors (LDLR, LRP-1 and LRP-2) that bind the amyloid beta 
precursor protein (APP), apolipoprotein E (ApoE) and alpha-2-macroglobulin (α2M) [64, 
65]; diphtheria toxin (DTR) or known as the precursor of heparin-binding epidermal 
growth factor ( HB-EGF) that do not have endogenous ligand and seems to be involved in 
inflammatory processes [66, 67]. The less specific route of transport is the absorptive-
mediated transport (AMT) which is based on electrostatic interaction between positive 
changes and negative ones of the endothelial cell membrane [68, 69] 
 
Figure 7: Transport routes across the blood brain barrier [70, 61]. 
2.2.2 Strategy of drugs delivery 
Because of the peculiar anatomic BBB conformation, it is difficult for drugs to cross it. 
For this reason it is important to consider the chemical and physical properties of the drugs 
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(pKa, molecular weight, liposolubility, etc.) and their binding to plasmatic proteins. There 
are two categories of therapeutic delivery: the invasive and non-invasive approaches [65, 
72]. 
An invasive approach is the temporary disruption of the BBB. The oldest method is the 
hyperosmolar disruption [73, 74, 75], where an osmotic shock shrinks the endothelial cells 
increasing the permeability. Several substances have been used for the osmotic disruption, 
but the most commonly used is the mannitol. The main problem of this method is that the 
increasing permeability do not operate in a selective manner, causing toxicity throughout 
the Central Nervous System [65]. Recently, another technique has been used as invasive 
methods, the ultrasound-mediated drug delivery using small (1-10 μm diameter) 
microbubbles that mechanically disrupt the tight junctions [76, 77]. This technique has 
shown major advantages to deliver therapeutic agents such as PEG-coated gold 
nanoparticles, small interfering RNA and stem cells [78]. The same effect could be 
achieved using vasoactive molecules, one example is the bradykinin that can selectively 
increase the capillary permeability of the brain tumor and not in the healthy tissue [79]. 
The alternative is the use of non-invasive strategies. Several molecules are able to cross 
the blood brain barrier using the passive diffusion due to their small molecular size (less 
than 500 Da), the high lipophilicity and lack of ionization at physiological pH [80]. Others 
approaches are inspired by other transport mechanisms, for example carrier mediated and 
receptor mediated transports. 
In recent years, nanomedicine has contributed to develop new strategies to cross the 
BBB delivering larger amount of therapeutic agents and reducing their toxicity [81]. The 
nanotechnology has allowed to functionalize the nanoparticles in order to optimize the 
drug loading and release kinetics, avoiding the plasma protein agglutination and their 
clearance through the reticuloendothelial system (RES) [82]. Nanocarriers are the new 
frontier of non-invasive method, because they improve drug delivery and increase 
solubility and drug protection [83]. The main types of nanocarriers are liposomes, 
polymeric nanoparticles, magnetic and solid lipid nanoparticles. Liposomes are small 
vesicles formed by one or more phospholipid bilayers showing low toxicity and the ability 
to deliver both hydrophilic and hydrophobic compounds. Liposomes are commonly 
cationic and PEGylated, that are able to cross the BBB through passive diffusion or 
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phagocytosis, thanks to their small size and their ability to bind the negative charge of the 
endothelium [84]. The presence of PEG on the surface is important because it impedes the 
clearance by the RES system [86]. Moreover the liposomes could be bound to a ligand in 
order to induce the receptor-mediated endocytosis. Liposomes have reduced toxicity, but 
show low encapsulation efficiency and poor storage stability [85]. Thanks to their 
biodegradability the polymeric nanoparticles are extensively used to deliver drugs into the 
CNS. They could be made of different polymers, such as poly lactic acid (PLA), poly ε-
caprolactone (PCL), poly aspartic acid, poly butylcyanoacrylate (PBCA), poly glycolic 
acid (PGA), poly D,L-lactide-co-glycolide (PLGA) and poly amino acids. Today the 
widely used polymers are PLA, PGA and PLGA because of their high biodegradability: 
being broken down into lactic acid and glycolic acid that are recycled into the Krebs Cycle 
[87]. Recently the chitosan (CS) has been considered as an interesting alternative, being 
abundant in nature, biodegradable and biocompatible polysaccharide [88]. An interesting 
alternative to liposomes and polymeric nanoparticles are the solid lipid nanoparticles 
(SLNs): that are stable, biodegradable in physiological conditions and with high drug 
loading capacity [89]. In recent years interest grew to ward magnetic nanoparticles 
(superparamagnetic iron oxide nanoparticles, or SPIONS) for their potential as a 
theragnostic tools [90]. 
2.2.3 Synthetic opioid peptide g7 
One of the most efficient approach to cross the BBB is to exploit the receptors 
expressed on it, such as the endocytic mechanism used by the β-endorphins and the 
opioids. Three opioid receptors were identified: mu, μ, are localized in hippocampus and 
thalamus; delta, δ is localized predominately in the striatum, limbic system, and cerebral 
cortex and kappa, κ, is one of the most abundant and ubiquitous in the CNS (κ1 and κ2) 
[91]. 
Taking advantage from this mechanism, the synthetic opioid peptide MMP-2200 (H2N–
l-Tyr-d-Thr-Gly-l-Phe-l-Leu-l-Ser–O–β-dlactose–CONH2) was able to cross the BBB 
[92], but it was chemically modified in order to eliminate the opioid effect. In fact the Tyr 
was substituted with the Phe and was obtained H2N–Gly-l-Phe-d-Thr-Gly-l-Phe-l-Leu–L-
Ser–O-β-D-glucose-CONH2 (g7 glycopeptide) [93]. Moreover to increase the BBB 
penetration in the C terminus the lactose residue was replaced with a glucose molecule 
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[94]. Several experiments demonstrated that the nanoparticles coated with g7 are able to 
cross the BBB after different routes of administration in vivo [95, 96], indeed it was 
possible to claim that this kind of nanoparticles cross the BBB at high rate in less than ten 
minutes reaching a high concentration in the grey matter. Furthermore the g7-NPs show a 
cellular tropism, and the concept for which the cellular uptake depends on specific cellular 
mechanisms was confirmed by their accumulation inside the neurons, interneurons and 
microglial cells, while were rarely found in astroglial cells [97]. The transport across the 
membrane occurs through the clathrin pathway that completes inside the lysosomes. 
Recently, was demonstrated the ability of the g7-NPs to deliver enzymes (high molecular 
weight molecules) in the animal model of lysosomal storage disorders 
(Mucopolysaccharidosis type I and II, MPS I and MPS II) [107, 108]. 
2.3 Alternative routes of administration 
In recent years the knowledge on drug transport across tissues has increased. In 
particular, considering diseases affecting the CNS, several alternative routes of 
administration were investigated. The most interesting approaches, which avoid the BBB, 
are the intra-ventricular and intranasal drug delivery. 
2.3.1 Ependymal barrier 
An important route of administration for several therapeutic agents could be the direct 
injection into the cerebral ventricles. 
The functional units in the ventricular system are single-layered cuboidal epithelial cells 
called the ependymal cells. The ependyma constitute a ciliated epithelium that derives 
from the neuroepithelium and is located at the interface between the brain parenchyma and 
ventricles in the central nervous system (CNS). The ependyma constitute barriers lining the 
ventricular lumen in the mature CNS, and performs important functions related to the 
development, morphogenesis, and physiology of the brain [98]. The ependymal cells have 
cilia, which influence the direction of the cerebrospinal fluid (CSF) bringing nutrients and 
neurotransmitters. The ependymal cells lining the ventricles are loosely joined together by 
special intercellular adhesion sites called desmosomes, which enable the cells to form a 
nearly continuous epithelial sheet over the surface of the ventricles and spinal canal. 
Because the junctions between the ependymal cells are loose, CSF is able to diffuse from 
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the ventricles into the central nervous system. Another cellular type is the tanycytes that 
don’t have cilia and play an important role in the transport of the hormones [99]. 
Several works have demonstrated the presence of adult neural stem cells in the 
subventricular zone (SVZ) [100]. Both in vitro and in vivo, it was observed that a 
subpopulation of ependymal cells CD133+ have the classical neural stem cell features 
which give rise stem/progenitor cells expressing Nestin, LeX or GFAP after brain injury. 
Moreover in adult ependymal the Notch signaling is active, that mean the neural stem cells 
are maintained in an undifferentiated quiescent state [101].  
The administration of the drug directly into the CSF, can decrease problems associated 
with intravenous delivery, such as systemic toxicity, metabolism of the drug in serum, and 
opsonization by serum proteins. 
However, this mode of delivery also implicates problems. Despite the improvement in 
drug concentration and half-life in the CSF, the distribution through the CFS is very slow. 
On the other hand, intra-cerebroventricular technique is invasive, and carries both risks of 
infection and a tendency to increase intracranial pressure through fluid injection [103]. 
Nevertheless, evidence from several animal LSD models with CNS manifestations 
suggests that gene therapy approaches with the transduction of cells lining the ventricles 
give raise to persisting levels of lysosomal enzymes in CFS, demonstrating a potential for 
clinical use [102]. Moreover the neural stem cells localized in the sub-ventricular zone 
could be transduced with the vector and, after differentiation, migrate in the brain. 
2.3.2 Intranasal drug delivery 
In the last twenty years, the nasal mucosa shows several interesting advantages for the 
treatment of different disease which affect the CNS (Parkinson’s, schizophrenia, epilepsy, 
and Alzheimer’s). Intranasal delivery bypasses blood brain barrier (BBB) and circumvents 
systemic extraction of drugs, targeting therapeutics to the brain via olfactory, rostral 
migratory stream (RMS) and trigeminal pathways [104]. This route is a non-invasive 
approach, which avoid systemic side effects. 
The nasal cavity is divided in two symmetrical halves by the septum. Each halves is 
composed by four areas: 
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I. Nasal vestibule; stratified squamous and keratinized epithelium with sebaceous 
glands. It has hairs called vibrissae, which filter the inhaled particles. Here the 
drugs and molecules absorption is difficult. 
II. Atrium; the anterior section is made by stratified squamous epithelium, while the 
posterior area is made by pseudostratified columnar cells presenting microvilli. 
III. Respiratory region; is the largest part of the nasal cavity responsible for 
humidification and temperature regulation of inhaled air. The nasal respiratory 
mucosa is considered the most important area for the systemic diffusion of the drug 
delivered by this route of administration. It is composed by the epithelium, 
basement membrane and lamina propria. The nasal respiratory epithelium consists 
of pseudostratified columnar epithelial cells, globet cells, basal cells and mucous 
and serous glands. Under the epithelium there are high permeable capillaries, 
nerves, glands and immune cells. 
IV. Olfactory region; pseudostratified epithelium which contained olfactory receptor 
cells. Its neuroepithelium is the only part of the CNS that is directly exposed to the 
external environment.[105] 
Despite the promising advantages, the intranasal administration has some limitations 
which could be overcome in future research. For example, the dimension of the drugs 
influence their absorption and delivery; therapeutic agents could be damaged by enzymes 
inside the nasal cavity; nasal congestion and allergies should interfere and the nasal 
mucosa might be damage by the administration [106]. 
2.4 Nanoparticles 
The history of nanoparticles dates back to the Mesopotamia in the 9
th
 century where the 
silver and copper nanoparticles were used for decorations [109]; then in the Middle Age 
was widely used in Europe to stain glass of the gothic cathedrals, indeed the different color 
of stained glass is due to size and shape of silver and gold nanoparticles [110]. The modern 
nanotechnology was born in the twentieth century when the technologies became more 
sophisticated and let to be closer to the nano-scale. Moreover in that times the progress in 
pharmaceutics focused its attention on the retarded and controlled drugs release [111]. The 
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first nanoparticle for drug delivery and vaccines was made in ‘70s by Speiser and 
coworkers [112]. 
The issue on using the transposon system is that the naked DNA is not able to cross the 
biological barrier and enter into the cellular nucleus and it has also to be protect from 
nucleases degradation. The other problem is to find the right formulation able to protect the 
plasmid and at the same time release it inside the cell without cellular toxicity. About this, 
the nanoparticles could help to overcome these problems. 
In recent years the research has developed various nanostructures composed with 
different materials, such as lipids (liposomes), polymers (nanoparticles; NPs) or metals as 
drug delivery systems, especially designed for intravenous administration. Many of them, 
especially the NPs, are characterized by their physicochemical properties, such as a small 
size has to be coupled with high surface-to-volume (S/V) ratios and the possibility to bind 
on the surface other (bio)materials [113]. Comparing nanoparticles with the traditional 
therapies it is clear that nanoparticles show some advantages, like the protection and 
stabilization of the active molecules from degradation, the chance to control the active 
molecules release and the ability to catch up the target site. Due to these characteristics, 
nanoparticles are able to improve the pharmacokinetic profile decreasing the circulating 
drugs doses avoiding systemic side effects [114]. 
2.4.1 Polymeric nanoparticles 
Over the last years polymeric nanoparticles obtained a particular importance on the 
fields of drug and DNA delivery into the brain [115]. Polymeric NPs are nanosized carriers 
(1-1000 nm) that could be made of natural or synthetic polymers. The most useful 
properties are the aqueous solubility or the possibility to be solubilized with less number of 
chemical modifications, the long-term stability in biological environments, the ability to 
control the therapeutic molecules release, biodegradability and the enhanced permeability 
through the tissues. Moreover the main advantage is that biodegradable polymers are 
broken down into biologically acceptable molecules that are metabolized by physiological 
metabolic pathway (Table 2) [85]. A wide different type of polymers are used; they could 
be hydrophilic, hydrophobic or hybrid amphiphilic copolymers and they are also produced 
by different technique, such as precipitation of polymers via emulsion/solvent evaporation, 
poly-condensation of monomers in aqueous emulsion or by simple self-assembly of 
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copolymers [118]. Based on the type of polymer and type of preparation method, the 
therapeutic element could be dissolved, entrapped, encapsulated or attached to a 
nanoparticle; and for these reasons they could take different shapes (Figure 8), for example 
nanospheres, nanoparticles or nanocapsules. Nanocapsules are similar to the liposomes or 
vesicles where the drug is surrounded by a polymer membrane that form a shell, while in 
the nanospheres the polymer forms a matrix in which the drug is dispersed. Recently the 
biodegradable polymer nanoparticles have resulted attractive as a carriers of DNA in gene 
therapy. The therapeutic molecules are left through different processes: solubilization, 
diffusion through the polymeric matrix, erosion or degradation of the polymer and swelling 
of the polymer [119]. Lots of various synthetic and semisynthetic polymers were 
developed, even if the natural polymers (polymers made of protein such as albumin and 
collagen, or made of polysaccharides such as chitosan and alginates) maintain a certain 
popularity. Currently, the most popular degradable material used for medical applications 
are polylactides (PLA), polyglucolides (PGA), poly lactide-co-glycolides (PLGA), 
polyanhydrides, polyothoesters, polycyanoacrylates and polycapolactone [85]. Comparing 
the natural with the synthetic polymers, the last one are more homogeneous in composition 
and have higher level of purity. Moreover the degradation kinetic is well known and the 
drug release period is prolonged from days to several weeks [120]. 
 
Table 2: Synthesis and degradation of most important polymers used in formation of nanoparticles [116]. 
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Figure 8: Different structure of nano-systems [117]. 
Unfortunately polymeric nanoparticles show some drawbacks and the most negative 
one is expressed in vivo after intravenous injection, where the nanoparticles are rapidly up-
taken by the reticuloendothelial system (RES) and distributed into the liver, the spleen and 
the bone marrow. The RES is a complex of phagocytic cells that originate from the bone 
marrow and are present in the whole body with an higher concentration in the liver 
(Kupffer cells), spleen and bone marrow. The nanoparticles are up-taken by RES because, 
after the injection, the NPs interact with blood plasma proteins and then with the 
membranes of macrophages (opsinization) that proceed with clearance [121, 122]. The 
clearance by the RES depends on size, surface charge and surface properties. It is well 
known that nanoparticles size determine their fate, and if the size is less than 10 nm they 
are rapidly removed by the renal clearance, while if the size is greater than 200 nm NPs are 
filtrated by the spleen and removed by the reticuloendothelial cells. Moreover the 
hydrophobic surface and negative charges promote the protein absorption causing the 
activation of the complement system [123]. To overcome this problem the NPs could be 
modified to extend the brain retention coating or linking them with PEGs; in fact the 
PEGylation improves the pharmacokinetic reducing the opsonization, the phagocytosis and 
the clearance by the liver [123, 124]. Another approach is based on the binding with 
surfactants, for example the polysorbate 80 (Tween 80) [125] or with the conjugation with 
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specific ligands (antibodies, proteins, peptides) taking advantage from the receptor-
mediated transcytosis or endocytosis [126]. 
2.4.1.1 PLGA 
The synthetic polymers PLA and PLGA, due to their biodegradability, have been 
approved by the FDA and the European Medicine Agency for parenteral administration in 
humans. Especially the PLGA prove to be useful for the encapsulation of different types of 
drugs, because the end-carboxylic groups is free to react for covalent linkages useful for 
the NPs functionalization. PLGA has been widely studied and several formulation 
protocols are described [127]. Other characteristics are its degree of crystallinity and its 
glass transition temperature, these features could be manipulated changing the molecular 
weight and the ratio between the two monomers (lactic and glycolic acid). For example a 
low ratio of the hydrophobic lactic acid and low molecular weights allow the water 
penetration affecting the drug release profile [128, 129]. 
There are different protocols PLGA NPs formulation: nanoprecipitation, simple 
emulsion and evaporation technique are used to encapsulate hydrophobic molecules, 
double emulsion and solvent evaporation is used to encapsulate hydrophilic compounds 
and proteins [130, 131]. These protocols have advantages, but have also limits such as the 
use of organic solvent and some processes that could damage the drug (for example the 
sonication and ultra-centrifugation); to avoid this drawback could be used the 
nanoprecipitation technique that does not use external supply of energy and does not 
undermine the drug stability. The therapeutic elements could be released following 
different profile: the solubility of the drug in water, the desorption, diffusion through the 
matrix and erosion or degradation [132]. 
The principal degradation pathway of the PLGA is the hydrolysis of the ester bonds 
resulting on formation of oligomers and lactic acid/glycolic acid monomers, which are 
recycled to Krebs Cycle and eliminated as carbon dioxide and water. It has been 
hypothesize that the process is divided in three steps: in the first phase there is a molecular 
weight loss, in the second appeared the degradation’s products (oligomers and monomers) 
and at the end there is the complete degradation [133]. This degradation process cause an 
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acidification of the cellular environment that could be dangerous if the NPs are loaded with 
pH sensitive molecules such as enzymes and proteins [134, 135]. 
At cellular level the first contact between the NPS and the cell membrane is often a non-
specific hydrophobic or electrostatic interaction and after the internalization the 
intracellular trafficking is not well known. The primary aim of the NPS is to protect the 
therapeutic element and release it in the right intracellular compartment, for example the 
cytosol for the proteins and siRNA and the nucleus for the DNA [136]. Lot of parameters 
influence the cellular uptake and the intracellular trafficking; in fact for a good NPs design 
should be considered the size, the charge, the shape etc. of the NPs and the different 
internalization mechanisms which are present in the different cell types. The endocytic 
pathway is the general route for the NPs internalization, in which the endosomes develop 
into lysosomes where the pH 4.5 could inactivate several types of therapeutic agents [137]. 
Destabilizing the endo-lysosomes organelles the PLGA NPS are able to escape from the 
lysosomes and they have the capacity to accumulate in the cytosol [138]. 
2.4.1.2 PLGA nanoparticles and plasmid DNA 
PLGA NPs could be useful to protect the plasmid DNA from the nuclease degradation 
and to increase its stability, even if there are difficulties to entrap the hydrophilic DNA 
inside the hydrophobic PLGA. Several methods have been developed (spray-drying, oil-in 
water solvent evaporation), but each of them could damage the DNA. To overcome this 
problem during NPs preparation have to be considered various parameters [139]. 
The first parameter is the selection of the appropriate molecular weight and the ratio 
between the two polymers, for example nanoparticles with high percentage of hydrophobic 
LA have reduced capability to bind and release the DNA due to reduced hydrolysis. 
Moreover high molecular weight has been associated with an high encapsulation 
efficiencies [140]. Another important aspect is the type and the rate of DNA that is 
encapsulated, indeed it is more difficult to integrate and release the supercoiled. In addition 
the encapsulation efficiency is influenced by the increasing amount of the DNA, even if it 
increase the DNA stability [141]. Other parameters are [139]: 
I. the surfactants that could influence the surface characteristics; 
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II. the pH that should damage the DNA; 
III. the excipients that could protect the DNA facilitating its uptake and its 
expression (for example the PEI is used to increase the delivery); 
IV. the PEGylation that increase the loading efficiency. 
Moreover the preparation method could influence the physic-chemical characteristics of 
the NPs. The technique most commonly used is the double-emulsion solvent-evaporation 
method (three phases: initial water solution with the DNA, intermediate organic phase with 
the polymer, water solution containing an emulsion) that allow to control the PLGA 
particles size, even if during the formulation the DNA could be nicked, mainly by the 
sonication [142]. To reduce the mechanical force, it is possible to use the spontaneous 
emulsification solvent diffusion (SESD) that allow to obtain small particles [143]. A 
modification of this method is the DNA-organic phase self-emulsification (DOPSM) in 
which cationic lipids are mixed with DNA in the organic phase and then is mixed with the 
PLGA forming spherical particles that are 1 or 2 μ in size [144]. Alternatively it is possible 
to use the cryo-preparation of the double emulsion method to preserve the plasmid DNA, 
even if the particles have diversity in shape and size. 
2.4.1.3 Polysaccharide nanoparticles 
Polysaccharides are the long carbohydrates molecules of monosaccharaides linked 
together by glucosidic bonds. They could be recovered from various resources, such as 
plant (pectin), algal (alginate) and animal (chitosan, chondroitin) [145]. Polysaccharides 
are stable, safe, non-toxic, hydrophilic and biodegradable biomaterials, that makes them 
suitable for applications in food, biomedical and environment fields [146]. Moreover they 
are very abundant in nature and their processing is low cost. The majority of the natural 
polysaccharides have several hydrophilic groups that make them soluble in water and 
promote non-covalent bonds with biological tissues and mucosal membrane. Moreover this 
characteristic allows to modify it chemically, for example binding drugs and targeting 
agents. Polysaccharides are the most promising materials adopted for nanoparticles 
preparations. The polysaccharides, used to produce nanoparticles, are divided in groups in 
base on their native charges: cationic (chitosan), anionic (alginate, heparin, hyaluronic 
acid) and nonionic (pullulan, dextran). There are various preparations mechanism, such as 
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chemical crosslinking, physical crosslinking, polyion complex and self-assembling [150]. 
The cross-linking could be chemical or physical. The physical crosslinking is based on 
ionic interactions between charged polysaccharides and ionic crosslinkers. Several studies 
demonstrate the successful on using these types of nanoparticles both in vitro and in vivo 
[147, 148, 149]. 
2.4.1.4 Chitosan 
Chitosan is a polysaccharide widely used for the manufacture of nanoparticles, 
especially in the gene therapy application, indeed it has been used as non-viral delivery 
system since 1995 [151]. Chitosan is a derivative from the partial deacetylation of the 
chitin, one of the most abundant polysaccharide in nature that is extracted from 
exoskeleton of crustacean, insects, fungi; and food industry waste (Figure 9). It is 
composed of randomly distributed β(1-4)- linked D-glucosamine and N-acetylglucosamine 
units. The amine groups make the chitosan a pH responsive polymer, in addition due to the 
amine groups positive charges it is possible to form polyplexes by electrostatic interactions 
with the negatively charged phosphate groups of DNA. Thanks to this property and its 
biocompatibility, biodegradability and non-toxicity, the chitosan is the most suitable 
cationic polysaccharide for gene therapy; in fact in the last decade several works have 
published papers on using chitosan complexed to plasmid DNA or miRNA, in particular 
for the treatment of different types of cancer [152]. However its biomedical application is 
complicated by its insolubility in water and in organic solvents. 
 
Figure 9: Schematic representation of chitin and chitosan polymer. 
At cellular level the chitosan polyplexes, if they are not bonded with specific targeting 
ligand, they interact with the cell membrane through unspecific electrostatic interactions 
and, depending on their size, they go into the cell by endocytic pathways (phagocytosis, 
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macropinocytosis, clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis 
(CvME) and clathrin- and caveolin- independent endocytosis). However the endocytosis is 
influenced by several factors, such as the size, the molecular weight etc. and also by the 
cell types (Figure 10) [153]. Once the polyplexes are inside the cell they have to escape 
from the endosome to avoid the degradation in the lysosomes. Several endolysosomal 
escape pathways are possible (such as “proton sponge”, membrane destabilization), even if 
it seems relevant in this processes the low molecular weight. The last membrane that the 
polyplexes have to cross is the nuclear membrane. To do that is possible to exploit nuclear 
pore complex if the particles are smaller than 10 nm, or they could incorporate the nuclear 
localization signal [154]. In vitro experiments have demonstrated that the chitosan MW 
and DA influenced all the steps involved in the transfection efficiency, such as the cellular 
up-take, intracellular trafficking and polymer decondensation [155]. Inside the cells the 
therapeutic agents could be released by diffusion, erosion and degradation. Currently, the 
mechanism of degradation is unclear. Anyway, several works have established that the 
polymer is degraded by chemical and enzymatic degradation (α-amylase and lysozyme); in 
fact chitosan could be degraded by enzymes able to hydrolyze glucosamine–glucosamine, 
glucosamine–Nacetyl-glucosamine and N-acetyl-glucosamine–N-acetylglucosamine 
linkages. In vivo, chitosan is degraded by several proteases; such as t chitinases which lead 
to the formation of non-toxic oligosaccharides of variable length. These oligosaccharides 
could be incorporated in metabolic pathways or could be excreted [156]. The two main 
organs involved in the chitosan degradation are the liver and the kidney. 
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Figure 10: The transfection process and the parameters/factors that influence each step [157]. 
2.4.1.5 Chitosan and plasmid DNA 
Several manufacturing processes were established, Chitosan may be simply complexed 
with nucleic acid by direct mixing of the positively charged Chitosan with negatively 
charged DNA, the binding occurs through electrostatic interactions. Through this easily 
method it is possible to obtain Chitosan nanoplexes. 
Several parameters of this technique could influence the plasmid integrity and the 
transfection efficiency and final plasmid DNA expression, for example the incubation time 
and the energy applied on the mixing. Despite there are different opinions about the 
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incubation time, the optimal incubation time to obtain the right formation of the polyplexes 
avoiding the formation of aggregates is between 15-30 minutes. Others parameters are: 
I. the ratio between the chitosan and the plasmid DNA, generally the 
nanoplexes are produced using an excess of the polysaccharide;  
II. the pH of the solution that could influence the size of the complexes. 
Moreover, other physic-chemical factors could affect the transfection efficiency, 
regardless the methods used. The most important are the molecular weight (MW), because 
it regulate the particle size, the binding affinity with the DNA, the cellular uptake and the 
dissociation to release the DNA; for this reason it is important the right balance between 
the plasmid and the polysaccharide. For example chitosan with the molecular weight more 
than 150 KDa (high molecular weight chitosans, HMWC) is able to protect very highly the 
DNA, but inside the cell the release is reduced; while if the chitosan have the molecular 
weight less than 150 KDa (low molecular weight chitosans, LMWC) releases easily the 
DNA cargo [158]. The second important factor is the deacetylation (DDA) that is the 
percentage of deacetylated primary amine groups in the chitosan molecule backbone, 
namely the number of potential interactions with nucleic acids. The DDA percentage 
reduction causes weaker electrostatic interactions, which provoke an easier DNA release 
and degradation [159]. The two parameters are strictly linked to each other, in fact it seems 
to be an appropriate DDA for each molecular weight. For the biomedical application the 
low molecular weight chitosans seems to be the optimal choice due to its high solubility at 
physiological pH [160]. 
Otherwise different techniques were set up in order to obtain more stable chitosan 
nanoparticles such as emulsion cross-linking, ionic gelation, spray drying and so on. 
The most popular method to obtain stable and biocompatible nanoparticles is the 
ionotropic gelation of chitosan by the addition of TPP (sodium tripolyphosphate) where the 
chitosan amino groups interact with anionic groups of tripolyphosphate. This small 
negative ion is suitable for medical application because at physiological pH it contains 
three negative charges and it is no toxic [167]. Moreover the TPP is able to create five 
ionic cross-linking points with cationic groups of chitosan that make it the best cross-
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linking agent for chitosan nanoparticles preparation. Nanoparticles parameters could be 
influenced by different factors: 
I. the size is effected by the chitosan/plasmid ratio, in fact increasing plasmid 
concentration the diameter of nanoparticles increase [170]; 
II. the surface charges is influenced by the pH, chitosan/TPP ratio and 
chitosan/plasmid ratio. 
Each parameters and the method of nanoparticles preparation affect the storage stability, 
loading, release performance and the interaction of the particles with different biological 
tissues where they are introduced. In order to obtain the best nanoparticles with the most 
suitable parameters, it is important to control the method of preparation [171].  
In order to prepare nanoparticles capable of endosomal escape with reduce toxicity,  
prolonged circulation and able to protect the nanoparticles from the serum proteins, the 
chitosan could be coated with poly(ethylene glycol) (PEG), dextrans, poly(N-vinyl 
pirrolidone), poly(glycerol methacrylate) and glycosoaminoglycans, such as heparin or 
hyaluronic acid (HA). Hyaluronic acid is useful when is required degradability and 
biocompatibility [167]. It was demonstrated that the chitosan nanoparticles coated with 
hyaluronic acid have an interesting potential as a gene delivery system with a reduced 
toxicity [172, 173]. 
2.5 Globoid Cells Leukodystrophy (or Krabbe’s Disease) 
Lysosomial storage diseases (LSDs) are caused by defects on lysosomal enzyme that 
compromise cell viability and cell integrity due to the accumulation or storage of non-
catabolized products. 
Krabbe’s disease was described the first time in 1916 by the Danish neurologist Knud 
Haraldsen Krabbe who found the presence of globoid cell in the brain [181, 182]. The 
presence of multinuclear (globoid) macrophages is the major histopathological change in 
white matter, linked with extensive demyelination and gliosis (Figure 11). 
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Figure 11:Typical histology of the white matter of a patient with infantile Krabbe’s disease. It's present a nearly 
complete loss of myelin and oligodendrocytes, which are replaced by severe astrocytic gliosis and lots of 
multinucleated macrophages (globoid cells) [183]. 
Krabbe’s disease or globoid cell leukodystrophy (GLD) is an LSD that affects both 
central and peripheral nervous system (CNS and PNS) in several species, including 
humans, rhesus, dogs, mice and sheep [184, 185, 186 187]. It is a rare autosomal recessive 
disorder in which extensive demyelination is accompanied by rapid and fatal 
neurodegeneration. GLD is caused by mutations in the β-galactocerebrosidase gene that 
codifies for the lysosomal enzyme galactocerebrosidase (GALC) that is essential for the 
catabolism of glycolipids, important component of myelin (galactocerebroside). The 
human GALC gene is located on chromosome 14 (14q24.3-34.1) and consists of 60652 bp. 
The organization of the human gene was studied in 1995 and it is composed of 17 exons 
and 16 introns [189]. The mouse GALC gene is located on chromosome 12 and consist of 
3723 bp. The cDNA is composed by 2278 nucleotides and it codifies for a protein of 668 
amino acids [190]. The mouse protein has the 83% of homology with the human 
aminoacidics sequence [191]. 
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The GALC protein is produced and glycosylated in the endoplasmic reticulum (ER) and 
trans-Golgi network (TGN), where is post-traslationally modified by N-linked 
glycosylation at four sites[192]. The precursor protein is approximately 80 to 85 KDa, the 
active form is composed of two subunits, a 50 to 52 KDa and a 30 KDa mature forms 
[193]. This process is obtained by the action of proteases probably localized inside the 
lysosomes. 
GLD severity and progression are variable and the age of onset can vary from the first 
few weeks of life (early infantile) through late-infantile, juvenile and adult clinical 
presentation (late-onset) [188]. 
2.5.1 Pathogenic Mechanisms 
Currently, researchers consider that GALC deficit results in the impaired degradation of 
two lipids: the primary substrate Gal-cer and the second one psychosine [182]. The Gal-cer 
is the most important glycosphingolipid in the brain tissue. These lipids are the major 
constituents of oligodendrocytes in CNS and of Schwann cells in the PNS[194]. The Gal-
cer synthesis takes place on the luminal surface of the reticulum. The amount of 
galactosylceramide in an immature brain is very low because its biosynthesis is more 
active when there is a rapid myelin turnover, so during the 18 months in humans and 15-25 
days in rodents[195]. During myelin turnover, Gal-cer is broken down into galactose and 
ceramide by GALC and these products are re-used in a separate remyelination pathway. In 
Krabbe’s disease the Gal-cer doesn’t broke down and free Gal-cer is able to draw 
infiltration of macrophages into the brain [196, 197]. Inside the brain the macrophages 
phagocytize Gal-cer and are transformed in multinucleated globoid cells. Anyway there is 
no proof that Gal-cer is toxic, indeed loss of myelin-forming cells is not attributed to Gal-
cer. The other lipid involved in the pathogenic process is the galactosylsphingosine or 
psychosine (psy). Its biosynthesis is not completely clear. In normal brain the 
concentration of psychosine is very low, while in the Krabbe affected brain it is highly 
accumulated into the oligodendrocytes [198; 182]. At cellular level has been demonstrated 
that psychosine accumulates in the CNS and PNS lipid rafts of GLD patients, and causes 
the membrane perturbation. In addition, psychosine induces dysfunction of several cellular 
pathways [199]. 
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2.5.2 Therapy 
To date the treatments for LSDs are transplantation of hematopoietic stem cell 
transplant (HSCT) or bone marrow cell transplantation (BMT), the gene therapy (GT) and 
the enzyme replacement therapy (ERT) (Figure 12). These therapies have been tested both 
alone and in combination. Notably the HSCT or BMT have to be initiated before the onset 
of symptoms, for this reason an early diagnosis is crucial. Another cell-mediated therapy 
could be the injection of the neuronal stem cell (NCS) transduced with a recombinant 
GALC-encoding viral vector directly into the brain. Twitcher mice treated with these 
modified cells have shown an increase on their life span; but the control Twitcher mice 
treated with non-trasduced cells show the similar increase in life span. This might be 
because the GALC overexpression in brain is not as critical or there are unspecific aspects 
of the disease that limit the effectiveness of GALC overexpression [200]. The ERT 
consists in a periodic enzyme administration in order to reduce and prevent the substrate 
accumulation, cause of the clinical phenotype. This approach shows some drawback 
obtain, such as the frequency of enzyme intravenous administration necessary to maintain 
a functional amount of Galc enzyme, the development of antibodies a-GALC and the poor 
crossing of the blood brain barrier (BBB) in an active form [201]. Substrate reduction 
therapy uses small molecule compounds to inhibit the synthesis of galactosylated lipids, 
including psychosine. The most promising treatment strategy is the gene therapy. The aim 
of this approach was from the beginning to modify the pathological cellular genome using 
virus-based approach (Adeno associated virus, AAV; retrovirus, RV; lentivirus, LV) or 
non-viral approach. The serotype AAVrh10 of the adeno-associated viruses (AAVs) is able 
to cross the blood brain barrier. Its capsid protein shows a high neural tropism. It was 
demonstrated in the mouse model of GLD, Twitcher mouse (see 2.5.3), an increased 
GALC activity after a single injection of AAVrh10 containing the mouse GALC cDNA. 
As a result these mice displayed normal functioning for an extended period. In addition, 
they showed that the time window for treatment could be larger than believed before [202]. 
Safety issues related to immune response of the adenoviral vectors and the possibility of 
insertional mutagenesis of viral vectors led researchers to develop non-viral approaches to 
treat LSDs [203]. The ideal vector should have a high translation efficiency, to guarantee a 
good protein production, to be able to incorporate DNAs fragments, not to be pathogenic, 
not to be immunogenic and, finally it should be easy to produce. To date, among the non-
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viral vector approaches the transposon systems are the most appealing vectors because the 
integrated gene has stable expression and they are less immunogenic and less toxic than 
viral vectors [204, 205, 206]. 
 
Figure 12: The triple- treatment strategy targets the primary and the two second consequences of GALC 
deficiency [207]. 
2.5.3 Animal Models 
There are different animal models of Krabbe’s disease that mimic the human pathology: 
dog, mouse and rhesus monkey.  
The Twitcher mouse was obtained by Dr. Jackson in the 1976. These mice show a 
leukodystrophy characterized by the ataxia (twitching) and globoid cells in the PNS and 
CNS. Twitcher mice are considered both as a Krabbe model and a model of congenital 
demyelination, indeed these mice are very useful both for therapy studies and to study the 
myelination and demyelination processes [208]. 20 days after birth, Twitcher mice show 
the ataxia and weakness of the hind paws and approximately after 40 days it is possible to 
find the psychosine accumulation inside the brain, the spinal cord and peripheral nerves.  
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In 1960 was described the first time the canine GLD [209]. In contrast to the Twitcher 
mice in which the signs of the disease are uniform, the canine model is more variable. In 
GLD canine model the ﬁrst signs appear between one and three months, and between eight 
and nine months the dogs become moribund. Similar to the Twitcher mice and human, the 
affected dogs have high level of psychosine, and a decrease myelination and accumulation 
of globoid cells [210]. 
Non-human primate model are often necessary before the therapy translation in clinic. 
The utility of this model is limited by the low reproduction rate of rhesus and the expensive 
maintenance cost [211]. 
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3 Objective 
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The aim of this dissertation is to assess the efficacy of a novel gene therapy approach in 
the mouse model of Globoid cell leukodystrophy (GLD) or Krabbe’s Disease, a disorder 
due to the deficiency of the lysosomal enzyme Galactocerebrosidase (GALC). It will be 
based on polymeric nanoparticles loaded with a transposon system called “Sleeping 
Beauty” which is able to transfer gene sequences through a cut and paste mechanism 
avoiding the onset of mutations. Moreover the nanoparticles will be coated with a short 
synthetic opioid peptide (g7) that is able to cross the blood brain barrier and enter into the 
central nervous system. 
First aim is to establish in vivo the ability of the opioid peptide bound to PLGA 
nanoparticles to cross the blood brain barrier through the optical imaging experiments. 
This ligand will be bound on the surface of the chitosan nanoparticles. Next the “Sleeping 
Beauty” will be encapsulated inside the chitosan nanoparticles that seems to be the suitable 
material to bind nucleic acids. 
At the end we will evaluated in vitro the Sleeping Beauty system efficiency through the 
analyses of the transposon copy number, the mRNA expression and the enzymatic activity 
using the traditional and polymeric approaches. 
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4 Materials and Methods 
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4.1 Plasmids 
The pcGlobin2-SB100Xco (transposase) and the pT2HB-CAG-Luc2 (transposon) 
plasmids (Figure 13) were kindly provided by Drs. Zsuzsanna Izsvàk (Max Delbück 
Center for Molecular Medicine, Berlin, Germany). 
 
Figure 13: Schematic representation of the pT2HB-CAG-Luc2 transposon. The red arrows are the two sequences 
recognized by the transposase enzyme. 
As first thing, the pT2HB-CAG-Luc2 plasmid was modified in order to insert the Renilla 
luciferase and the neomycin resistance sequences. In order to obtain this new plasmid, it 
was adopted a strategy that allows to create a multiple cloning sites (MCS, Addgene) in 
relevant position for the cloning strategy. As donor of the sequence that codify for a 
Renilla luciferase/neomycin fusion protein has been chosen the commercial pmirGlo 
vector (Promega). About twenty nucleotides were annealed (5’-
ATCCGCCGGAATTCCGGCCAT-3’; 3’-GGCGGCCTTAAGGCCGGTAGC-5’) to 
obtain a double strand sequence containing the EcoRI restriction site which is necessary to 
clone the Renilla luciferase/neomycin fusion sequence inside the original pT2HB-CAG-
Luc2. The pmirGlo vector was properly cut using the enzymes BamHI and ClaI in order to 
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insert the short sequence containing the useful EcoRI restriction site downstream the 
Renilla luciferase/neomycin fusion sequence (Figure 14). 
 
 
Figure 14:Schematic representation of the pmirGlo vectors. Top: original sequence of the commercial vector; 
bottom: pmirGlo sequence after the modification with the oligonucleotide containing the EcoRI restriction 
enzymatic site (red circle). 
Afterwards, due to the presence of these new cut sites, all the interesting elements have 
been cloned inside the original transposon using the EcoRI and NotI restriction enzymes. 
This process allowed us to obtain a transposon with the Firefly luciferase and the Renilla 
luciferase/neomycin fusion protein with their own promoter. All the aforementioned 
sequences have been inserted between the two regions recognized by the transposase 
46 | P a g .  
 
(inverted terminal repeat sequences, IR/DR (L) e IR/DR (R)). We obtained a new 
transposon called pT2HB-CAG-Luc2-Ren/neo (9361 bp) (Figure 15). 
 
Figure 15: Schematic representation of pT2HB-CAG-Luc2-Ren/neo transposon. The purple circles are the 
restriction enzyme used for the cloning strategy; the red arrows are the regions recognized by the transposase 
enzyme (IR/DRs). 
For the second modification the Firefly Luciferase sequence was replaced with the 
murine GALC codifying sequence that was obtain from in-house Lentiviral vector. We 
designed the primers in order to have at the two extremities the sequences of restriction 
enzymes (BglII and FseI) useful for our cloning strategy (Forward_BglII-5’-
GGAAGATCTTCCGTCATGACCGCCGCC-3’; Reverse_FseI-5’-
GATGGCCGGCCTGTGGACTAGCGAGCA-3’; Ta=64°C). The cDNA GALC sequence 
was amplified from the donor vector using the AccuPrime DNA Polymerase (Invitrogen) 
following the manufacture’s protocol. At the end we obtained a new transposon called 
pT2HB-CAG-mGALC-Ren/neo (9663 bp) (Figure 16). 
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Figure 16: Schematic representation of the final transposon plasmid: the purple circles are the restriction enzymes 
used to clone the mGALC sequence instead of the Firefly luciferase sequence; the red arrows are the site 
recognized by the transposase enzyme (IR/DRs). 
The pCRII-β-Globin plasmid, as standard for the real time PCR experiments, was 
created employing the commercial kit TA Cloning Kit Dual Promoter (Invitrogen) 
following the manufacter’s protocol. 
T4 DNA ligase and restriction enzymes were purchased from New England Biolabs and 
for the reaction set up has been followed the manufacture’s protocol. One shot TOP10 
Electorocomp E.coli were commercially provided from Invitrogen. QIA quick gel 
extraction kit and Hispeed Plasmid Midi kit were purchased from the Qiagen (Valencia, 
CA). Sanger sequencing allowed us to check the right transposon constructions. 
4.2 Plasmids sequencing 
The Sanger sequencing reactions were carried out with BigDye Terminator v. 3.1 mix 
(Applied Biosystems), buffer 10X (Applied Biosystems), Betaine 5M (Sigma Aldrich), 4 
pM of primer, and 200 ng of plasmid template in a final reaction volume of 10 μl. Cycle 
conditions were an initial denaturation at 96° for 3’, then 30 cycles of 96° for 30”, (ta) 
annealing temperature for 15”, 60° for 4'. Excess dye terminators were removed using 
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BigDye® XTerminator™ Purification Kit (Applied Biosystems). Samples were 
electrophoresed on an Applied Biosystems 3500DX Genetic Analyzer CE-IVD instrument, 
using 50 cm capillary arrays and POP-7 polymer. Data were analyzed using SeqScape 
version 2.7 of Sequencing Analysis. 
4.3 Cell culture 
For in vitro experiments were used different type of cells. 
For the preliminary studies were used the HELA cell line and the CHO cell line. The 
HELA line is an immortal cell line derived from human cervical cancer cells and they 
grow in the high glucose formulation of DMEM (with 4500 mg/L glucose, L-glutamine 
(0.292 g/L), sodium bicarbonate (3.7 g/L) without sodium pyruvate) supplemented with 
10% fetal bovine serum. The CHO is an epithelial cell line derived from the ovary of 
Chinese hamster and that grows in serum-free CHO medium (CHO-S-SFM II, Gibco). 
The SVG cell line is an immortalized human fetal astrocyte cell line, that synthesizes a 
replication-proficient SV40 T-Ag. The cells grow in the high glucose formulation of 
DMEM (with 4500 mg/L glucose, L-glutamine (0.292 g/L), sodium bicarbonate (3.7 g/L) 
without sodium pyruvate) supplemented with 10% fetal bovine serum. 
The primary cell culture of Human Fibroblast were obtained from foreskin. The cells 
grow in the RPMI 1640 medium (with 300 mg/L L-glutamine, 2000 mg/L glucose, sodium 
bicarbonate (2000 mg/L) and without sodium pyruvate) supplemented with 15% fetal 
bovine serum. 
The primary cell cultures of Human Fibroblast presenting the Krabbe disease (ML) 
grow in the RPMI 1640 medium (with 300 mg/L L-glutamine, 2000 mg/L glucose, sodium 
bicarbonate (2000 mg/L) and without sodium pyruvate) supplemented with 15% fetal 
bovine serum. 
The Human Oligodendrocytic (Glial) (MO3.13) Cell Line is an immortal human-human 
hybrid cell line that express phenotypic characteristics of primary oligodendrocytes. The 
cells were provided by Dr. Marco Cecchini (CNR-Istituto Nanoscienze, Pisa). The cells 
grow in the high glucose formulation of DMEM (with 4500 mg/L glucose, L-glutamine 
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(0.584 g/L), sodium bicarbonate (3.7 g/L) without sodium pyruvate) supplemented with 
10% fetal bovine serum. 
Human Glioma cell line A172 (ECACC, UK) were maintained in humidified 
atmosphere (5% CO2) in RPMI-1640 medium supplemented with 10% fetal bovine serum, 
2 mM l-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
Before every in vitro experiments, the culture cell medium of each cell line was tested 
for the absence of mycoplasma through a specific PCR (F_GPO 5’-
GGGAGCAAACAGGATTAGATACCCT-3’, R_MGSO 5’-
TGCACCATCTGACACTCTGTTAACCTC-3’; Ta=55°C). 
4.4 Cell transfection 
All the cells were transfected with the nucleofector Amaxa (LONZA). In order to 
stabilize the best nucleofector Amaxa protocol that allows a good transfection efficiency 
and a good cell viability, each cells type were transfected with the commercial vector 
pmaxGFP™. The cells were resuspended with 100 μl of Ingenio Electroporation Solution 
(Mirus) and to the solution were added 2μg or 1μg of transposon plasmid and 500 ng or 
250 ng of pcGlobinSB100Xco transposase in a 4:1 or 2:1 ratio. The mix solution was 
transferred into a certified cuvette that was inserted inside the Nucleofector Cuvette holder. 
500 μl of culture medium was added to the cuvette and the cells were gently transferred 
into the culture dish. The clones selection was performed using the 800μg/μl of G-418 
Sulphate Geneticin Solution 50 mg/ml (EuroClone). 
4.5 Luciferase assay 
To investigate the luciferase expression we used the commercial kit "dual-luciferase 
reporter assay" (Promega); this kit allows to retrieve, at the same time, the expression of 
the two enzymes (Firefly Luciferase and Renilla Luciferasi) in order to normalize the data 
of the Firefly expression based on the data obtained from the Renilla luminescence. The 
test was performed after 24 hours from the transfection and after the neomycin selection. 
The cells, which were obtained from ¼ of one well of six-well plate (~7,5x10^4 cells), 
were treated with Passive Lysis Buffer 1X and 4 μl were added into the cuvette with 20 μl 
of the reagent LARII that allows to read the Firefly Luciferase with the TD-20/20 
Luminometer (Turner Designs). After the reading, inside the same cuvette, 20 μl of the 
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reagent Stop&Glo 1X were added to the reaction mix. This reagent permits to read the 
Renilla Luciferase fluorescence. 
4.6 DNA extraction 
The cell DNA was extracted with the QIAMP kit (QIAGEN) following the 
manufacture’s protocol and with the classical phenol-chloroform method [160]. The pellet 
was dried at room temperature and then was resuspended with 50 μl of sterile water. The 
DNA concentration was measured with the NanoDrop-1000 (Thermo Scientific). 
4.7 RNA extraction and RT  
For the RNA extraction was used the commercial kit EuroGold total RNA (EuroClone) 
from ~0,3x10^6 cells and the RNA was eluted with 50 μl of RNAsefree water pre-warmed 
at 70°C. At the end the RNA concentration was measured with the NanoDrop-1000 
(Thermo Scientific). 1 μg of total RNA was retro-transcribed with the GoScript Reverse 
Transcription System (Promega) following the manufacture’s protocol. 
4.8 Real Time PCR 
The quantitative real-time PCR reactions were achieved on 7900HT Fast Real-Time 
system (Applied Biosystems) in order to investigate different aspects after the transfection 
experiments. The singleplex reaction was run in duplicate with a final volume of 20 μl 
using SyberGreen chemistry (primer concentration of 10 μM). Cycle conditions were an 
initial denaturation at 95° for 10’, then 40 cycles of 95° for 15”, ta° for 15”, 60° for 1' and 
the final melting curve. 
4.8.1 Absolute Real-Time quantification 
After 48 hours from the transfection experiments the plasmid DNA was isolated from 
the cells through the phenol-chloroform method. 25 ng and 5 ng of total DNA were 
analyzed in absolute real time PCR, that was carried out with Power Syber Green (Life 
Technology). To set up this experiment we designed two different pair of primers, one able 
to recognize at the same time the episomal and the excision plasmids (F_PCR2 5’-
GGTATCAGCTCACTCAAAGG-3’, R_PCR2 5’-CTTTTTACGGTTCCTGGCCT-3’; 
Ta=50°C) and the other one able to anneal only on the episomal plasmid (F_PCR4 5’-
GGCGATTAAGTTGGGTAAC-3’, R_PCR4 5’-AACTGTATAGGGATCCGAGC3’; 
51 | P a g .  
 
Ta=53°C). In order to normalize data, the same samples were amplified with the β-globin 
primers (β-GLOBIN_R 5’-CAACTTCATCCACGTTCACC-3’, β-GLOBIN_F 5’-
ACACAACTGTGTTCACTAGC-3’; Ta=55°C). After 48 hours it is possible to establish 
the relative excision activity. 
Average copy number of transgenic cell populations were measured from transfected 
and selected cells. 50 ng and 5 ng of genomic DNA were analyzed in absolute real time 
PCR (SyberGreen method). To set up this experiment were used primers that annealed on 
the sequence recognized by the Transposase (F_IRDR_R 5’-
ACCCACTGGGAATGTGATGA- 3’, R_IRDR_F 5’-CCTGTCTTAGGTCAGTTAGG-3’; 
Ta= 55°C). In order to normalize data, the same samples were amplified with the β-globin 
primers (β-GLOBIN_R 5’-CAACTTCATCCACGTTCACC-3’, β-GLOBIN_R 5’-
ACACAACTGTGTTCACTAGC-3’; Ta=55 °C). 
The absolute quantification was achieved by a serial dilutions of two plasmids (pT2HB-
CAG-mGALC-Ren/neo and pCRII-β-Globin plasmids) which contained inside the specific 
sequences amplified by the primers. The standard curve was created using a range between 
300000 and 30 copies. The following formula has been applied to establish the right 
correlation between the plasmid copy number and the ng to put into the reaction. The mass 
of a single plasmid molecule was calculated applying the formula: 
Plasmid length (bp) x 1,096e-21 g/bp = mass (g) 
Subsequently the plasmid mass was multiply by the copy number of interest to obtain 
the mass of plasmid DNA needed in each reaction. 
4.8.2 Relative Real-Time quantification 
The relative gene expression was measured amplifying a serial dilution of cDNA (100 
ng, 25 ng, 6,25 ng) using the primer that recognise the GALC’s mRNA (K12_F_RT 5’-
TAGGAGCTCACTATCCTGGA-3’, K12_R_RT 5’-AGGCTGTTGGAGTCGCATAT-
3’). The β-Actin house-keeping gene (F_β-Actin 5’-TAAGGAGCTGTGCTACG-3’; R_ β-
Actin 5’-GCTCATTGCCAATGGTGATG-3’) amplification allows to normalize the data. 
Cycle conditions were an initial denaturation at 95° for 10’, then 40 cycles of 95° for 15”, 
58° for 15”, 60° for 1' and the final melting curve. The raw data were analyzed using the 
ΔΔCt method. 
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4.9 Protein extraction and quantification 
For the protein extraction the cells were harvested from a well of a six-well plate 
(~0,3x10^6 cells) and it was resuspended with 200 μl of M-PER Mammalian Protein 
Extraction reagent (Thermo Scientific) and mixed for 5 minutes at room temperature. Then 
it was centrifuged for 10 minutes at 14000xg at 4°C. After this step the surfactant was 
collected into a new clean tube and preserved on ice. The samples obtained from this 
procedures were quantified through Lowry’s method or BCA protein assay. The protein 
quantification was performed with LAMBDA 40 UV/VIS Spectrometer (PerkinElmer 
instruments) [161]. 
4.10 Enzymatic assay 
The protein’s extracts were diluted 1:6 and 1:18 with NaP buffer pH6 and used for the 
enzymatic assay. The fluorogenic substrate 4-methylumbelliferyl-β-D-galactoside was 
purchased from Sigma Life Science and dissolved in Citrate buffer, pH3.4. The enzymatic 
assay was performed mixing 40 μl of substrate with 20 μl of samples’ dilutions and 
incubated 30 minutes at 37°C in darkness. This allows to measure the total activity of β-
GAL plus GALC. In order to measure only the GALC activity, it was added to the mix 
reaction 3 μl of AgNO3 3mM. After 30 minutes of incubation, the reactions were stopped 
with 290 μl of 0.4 M Glycine/NaOH, pH10.4. The reactions were performed in black 96-
well plate and the fluorescence of released 4-methylumbelliferyl was measured on Glomax 
Multi Detection System instrument (Promega) and UV optical kit (excitation at 360 nm 
and emission of 450 nm). The raw data were analyzed with the formula: (IF x dilution x 
total assay volume)/(slope x time x sample)=mU/ml. This value is multiply by the total 
amount of protein. The enzymatic activity was expressed as nanomoles of substrate 
hydrolyzed per minute and normalized from milligram of protein. 
4.11 Plasmid labeling 
In order to follow the plasmid encapsulation processes, each plasmids was labeled with 
Label IT Tracker following the manufacturer’s protocol. Briefly, 5 μg of plasmid DNA 
was mixed with 2,5 μl of Label (ratio 1:0.5; weight: volume), 5 μl of Buffer A 10X in a 
final volume of 50 μl. The labeling reaction was incubated at 37°C for one hour. The 
labeled plasmid DNA was separated from the unattached label by ethanol precipitation 
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using 1/10 volume of NaCl 5M, two volumes of ice cold 100% ethanol and incubated for 
one hour (or overnight) at -20°C. After a centrifugation for 40 minutes at 14000g at 4°C, 
the supernatant was eliminated and the pellet was washed with 70% ethanol and 
centrifuged for 30 minute at 14000g at 4°C. Then it was reconstituted with 10 μl of sterile 
water. 
4.12 Cell labeling and fixation 
After the transfection, the cells were placed on a coverslip and after the appropriate time 
they were labeled with 5μg/ml of Wheat Germ Agglutinin Conjugates (WGAC 488- 
LifeTechnologies) diluted in culture medium to dye plasmatic membrane for 10 minutes at 
37°C. The labeling solution was removed and the cells were washed twice with PBS 
solution. Then the cells were fixed with PFA 4% (SigmaAldrich powder 95%) for 20 
minutes at 37°C and washed for three times. To mount cells on a slide, the Vectashield 
Hardset (Vector laboratories Inc. Burlingame, CA ) was dispensed onto the specimen; in 
this way the DAPI coloured the cellular nuclei. To analyze the slides we have used the 
inverted microscope Axioplan 2 and the object 40X (ZEISS Oberkochen German), the 
images were acquired with Axiocam MRc and modified with the corresponding program. 
4.13 Cell viability assay 
In order to evaluate a range of nanoparticles toxicity, the MTT assay has been 
performed. These is a colorimetric assay for evaluating cell metabolic activity. The 
NAD(P)H-dependent cellular oxidoreductase enzymes reflect the number of viable cells 
because these enzymes are able to reduce the tetrazolium dye MTT 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (SIGMA-ALDRICH) to its insoluble formazan, 
which has a purple color. 24 hours before the experiment the cells were plated in a 96-
wells plate (~1,25x10^4 cells). 12 wells were used as controls. After 24 hours, the cells 
should be attached to the well and it was possible to change the cell medium with the 
medium with the appropriate nanoparticles concentration. The plate was incubated at 37°C, 
5% of CO2 for the established period of time. After the treatment time it was possible to 
add the MTT reagent diluted 1:10 inside each well (the filtrated stock solution is 5 mg/ml 
PBS). The 96-wells plate was incubated for 4 hours and then was added 100 μl of 
isopropanol, in this way the sale was resuspended. Each well is read at wave length of 
570nm using Glomax Multi Detection System (Promega). 
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4.14 Animals 
Balb/c mice of approximately 20 g and 6 weeks of age were obtained from Harlan 
Laboratories (San Pietro al Natisone, Udine, Italy) and maintained under pathogenfree 
conditions and on low-fluorescence diet [162].All the experimental procedures were 
performed according to the guidelines of the European (86/609/EEC) and the Italian 
(D.L.116/92 and subsequent addenda) law. 
4.15 The g7 opioid peptide bound to PLGA nanoparticles 
4.15.1 The g7-PLGA nanoparticles preparation and characterization 
The g7 peptide bound to PLGA NPs were provided by Prof. Tosi [94] in order to 
evaluate the ability of this peptide to cross the BBB. NPs preparation has been performed 
in different phases. First of all the PLGA polymer was bound with the DY 675 
(C44H53N4O5SCI; Mol. Wt. 785.45; Dyomics; Jena, Germany) to obtain DY-PLGA, and 
then the g7 was conjugated in according to the already described protocol [174]. The 
nanoparticles DY-g7-PLGA were obtained in accordance with the nanoprecipitation 
procedure. To evaluate the morphology of DY-g7-NPs was performed a scanning electron 
microscope (SEM) (XL-40 Philips, Eindhoven, The Netherlands). The samples were 
coated under argon atmosphere with a 10-nm gold palladium thickness (Emitech K550 
Supper Coated, Emitech LTD, UK). Photon correlation spectroscopy (PCS) and laser 
Doppler anemometry have been used to analyze the DY-g7-NPs size (in distilled water) 
and zeta potential (z-p) using a Zetasizer Nano ZS (Malvern, UK; Laser 4 mW He–Ne, 
633nm, Laser attenuator Automatic, transmission 100% to 0.0003%, Detector Avalanche 
photodiode, Q.E>50% at 633nm,t  = 25 C). The results were normalized with respect to a 
polystyrene standard solution. 
4.15.2 In vivo imaging 
To performed in vivo imaging the PLGA NPs were conjugated with dye 675 that emit at 
seven hundred nm. These NPs have been injected into the tail vein of Balb/C mice and 
then the images were acquired with Pre-clinical optical imaging system eXplore Optix 
(ART Advances Research Technologies Inc). The 12 mice were divided in two groups, the 
control group was injected with 100μl of nanoparticles without the peptide g7 and the other 
one was treated with 1 ml of nanoparticles functionalized with the peptide g7 (8 mg). 
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During the experiments the mouse was anesthetized with a gaseous anaesthesia and placed 
in the holder that is an heated plate. The plate is automatically transferred into the laser 
chamber, where there is a pulsed laser, exciting the region previously selected and 
inducing a fluorescence emission which is detected by a specific detector. A prescan image 
was acquired before labeled probe administration. Fluorescence emission was collected at 
700nm. At the end of the imaging analysis, the mouse was allowed to recover from the 
anaesthesia. To evaluate the ability to cross the BBB the two groups of mice were analysed 
after ten minutes (t=0) and two hours (t=2h) from the injection. 
4.16 Chitosan 
4.16.1 Chitosan/plasmid DNA nanoplexes preparation 
In order to obtain chitosan nanoplexes has been used polydisperse polysaccharide with 
average molecular weight of 50 KDa, with 87% of deacetylation degree, in form of 
hydrochloride salt at pH5 (NOVOZYME). The chitosan has solubilized with MilliQ water, 
filtered using a 0,22 μm filter and then has been obtain a solution CHIT1 with a 
concentration of 10 mg/ml. The stock solution has been diluted in order to obtain CHIT2 
(0,1 mg/ml), CHIT3 (0,5 mg/ml) and CHIT4 (2,5 mg/ml). The suitable amount of chitosan 
has been added to the vector to obtain three different solution with different ratio between 
chitosan and DNA (maintaining constant the amount of DNA). The concentration of 
chitosan used for the preparations was suitable to have the constant final volume of 
complexation. Then the solutions were lightly stirred for 30 minutes, froze and dried. 
Before the in vitro experiments each preparations were resuspended with sterile water 
(Figure 17). 
 
Figure 17: Schematic representation of the chitosan nanoplexes preparation. 
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4.16.2 Gel retardation assay 
The efficiency of the complexation between the chitosan and the plasmid DNA was 
evaluated through the gel retardation assay using 1% agarose gel. 200 ng of each chitosan 
polyplexes preparations were loaded onto the gel with 2 μl of loading dye. In the same gel 
was loaded the same amount of the naked plasmid. The plasmid retardation has been 
visualized under UV transillumination. 
The stability of the chitosan-plasmid DNA nanoplexes was evaluated using the gel 
retardation assay after the samples were kept at -20°C for 2-3 weeks. 
4.16.3 Cellular uptake 
For the purpose of evaluating the uptake of the chitosan/DNA complex, 0,3x10^6 
MO3.13 cells were plated on a well of 6-wells plate and were tested different conditions: 
1. C1: 1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine (~200ng of chitosan) 
2. C2: 1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine (~1μg of chitosan) 
3. C3: 1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine (~5μg of chitosan) 
4. D1: 250 ng of pcGlobin2-SB100Xco+Fluoresceine (~50 ng of chitosan) 
5. D2: 250 ng of pcGlobin2-SB100Xco+Fluoresceine (~250 ng of chitosan) 
6. D3: 250 ng of pcGlobin2-SB100Xco+Fluoresceine (~1,25 μg of chitosan) 
7. C1+D1: (1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine) + (250 ng of 
pcGlobin2-SB100Xco+Fluoresceine) (~250 ng of chitosan) 
8. C2+D2: (1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine) + (250 ng of 
pcGlobin2-SB100Xco+Fluoresceine) (~1,250 μg of chitosan) 
9. C3+D3: (1μg of pT2HB-CAG-mGALC-Ren/neo+Rhodamine) + (250 ng of 
pcGlobin2-SB100Xco+Fluoresceine) (~6,250 μg of chitosan) 
The cells were incubated for two and six hours at 37 °C, then they were labeled with 
Alexa Fluor 350 WGA, fixed with PFA 4% and mounted on slide. 
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4.16.4 Chitosan/TPP-hyaluronic acid nanoparticles preparation 
Plasmid DNA loaded nanoparticles were synthesized by the ionotropic gelation 
technique between positively charged chitosan and negatively charged TPP as previously 
reported in literature [175] (Figure 18). Chitosan was dissolved in HCl (4.6 mM) at 
concentration of 2 mg/ml (w/w) and the pH was adjusted to 4.9 by the addition of 
appropriate volumes of NaOH. Then, a 0.5% (w/w) solution of the anionic crosslinker, 
pentasodium tripolyphosphate (TPP), was prepared in water. All the solutions were filtered 
with a 0.22 μm filter to remove traces of solid particles. In order to promote the 
encapsulation of nucleic acid, the pcGlobin2-SB100Xco-Fluorescein  (2μg/μl) was added to 
the TPP solution to assure that no interaction would occur between negatively charged 
DNA and positively charged chitosan. Then, the complexes were obtained at different N/P 
ratio, adding dropwise the required amount of TPP solution/plasmid DNA to 4 mL of 
chitosan solution under magnetic stirring (300 ± 50 rpm) for 30 min. N/P ratio was defined 
as the molar ratio of the positive amino group of chitosan and the negative DNA phosphate 
group. The formulated nanoparticles were then pelleted by centrifugation at 17,000 g for 
30 min. Chitosan/PcGlobinSB100Xco2-Fluorescein nanoparticles were dispersed in a 100 
mM acetic acid/acetate buffer (pH 5) and slowly added to an equal amount of hyaluronic 
acid (MW < 10 kDa) in acetate buffer and stirred for 30 min. 
 
Figure 18: Schematic representation of the ionotropic gelation technique. 
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4.16.5 Chitosan/TPP-hyaluronic acid nanoparticles characterization 
Nanoparticles size and zeta potential were determined by dynamic light scattering 
(DLS) using Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, UK). 
To determine the hydrodynamic diameter by DLS, nanoparticles were diluted in milliQ 
ultrapure water as a dispersant medium, followed by 30 min incubation at room 
temperature prior to analysis. Size measurements were performed in automatic mode with 
a scattered light detection angle of 173°. The reported particle size was obtained as an 
intensity distribution by cumulative analysis performed in the zetasizer software (version 
6.20). All the measurements were performed in triplicate. The zeta potential values (mV) 
were calculated from the electrophoretic mobility using the Smoluchowsky relationship. 
The experiments were performed in triplicate and an average of 100 measurements was 
acquired individually for each sample. 
4.16.6 Chitosan/TPP-hyaluronic acid nanoparticles encapsulation efficiency 
The encapsulation efficiency (EE) of the pDNA inside the nanoparticles was determined 
after isolation by centrifugation (10 000g, 30min, 25°C) and recovery of the supernatant. 
The amount of unbounded pDNA was determined by UV–vis analysis (Shimadzu UV–vis 
1700 spectrophotometer), as reported by [176]. The encapsulation efficiency was 
calculated as follows: 
EE(%) = Amount Total pDNA − Amount of pDNAsupernatant 
Amount of Total pDNA × 100. 
4.16.7 Chitosan/TPP-hyaluronic acid nanoparticles up-take efficiency 
Human Glioma A172 (ECACC, UK) cells were seeded at a density of 10
5
 cells/cm
2
 
onto black 24-well plates. On the second day, the cells were pre-incubated with Hank's 
buffered salt solution (Hyclone, Italy) for 15 min, and the medium was replaced with the 
suspension of nanoparticles and incubated for 30, 60, and 120 minutes at 37°C. Then the 
cells were washed with ice-cold PBS for five times and solubilized in 400 μl 1% Triton X-
100. Fluorescence in cell lysates was quantified with a spectrofluorometer (Cytation 5, 
BioTeck). In addition, cell lysates were subjected to BCA protein assay. The uptake of 
nanoparticles by A172 cells was expressed as percentage of nanoparticles uptaken per mg 
cell protein. 
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4.17 Statistical analysis 
The experiment were generally performed in triplicate and the data were reported as the 
mean ± standard deviation. The Student’s t-test and one-way ANOVA test were performed 
to establish the significance of the results (P< 0.05). The graphics were made using Prism 7 
GraphPad software, Inc, USA. 
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5 Results 
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5.1 In vitro experiments 
In vitro preliminary experiments were performed to establish the efficacy of the 
Sleeping Beauty System using a traditional transfection method. Several types of cells 
were employed to measure the transposase excision activity, the transposon copy number 
and the enzymatic activity. 
5.1.1 Cell transfection 
To perform in vitro experiments the cells were co-transfected with the transposon and 
the transposase using the nucleofector Amaxa (LONZA). First of all, for each different cell 
line, we established the best nucleofection program testing different protocols suggested by 
the Lonza company using the commercial vector pmaxGFP™. After 24 hours the 
transfection efficiency was established verifying the expression of the green fluorescent 
protein (GFP) (Figure 19). 
 
Figure 19: Example of cell transfection with the commercial vector pmaxGFP. Here 2μg of vector were used to 
transfect the MO3.13 using the T-020 program. Scale Bar indicates 100μm. 
According to the preliminary test we were able to determine the right transfection 
protocol for each different cell line; the protocols reported in Table 3 are the best 
compromise between cell viability and transfection efficiency. 
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Cells Nucleofector program Cell number per reaction 
HELA I-013 2 x 10^6 
CHO U-023 1 x 10^6 
Human Fibroblast U-023 0,5 x 10^6 
SVG D-023 2 x 10^6 
MO13.3 T-020 2 x 10^6 
Table 3:Transfection conditions. 
5.1.2 Luciferase assay 
When the new vector was obtained, we wanted to establish the transfection efficiency 
and the right ratio between the transposon and the transposase to use. For this reason 
HELA and CHO cell lines were co-transfected with pT2HB-CAG-Luc2-Ren/neo 
transposon and the pcGlobin-SB100Xco transposase. Moreover as a control the cell lines 
were transfected with only the transposon. After 24 hours post transfection the cells were 
selected adding in culture medium neomycin G-418. The vector has the neomycin 
resistance sequence so the medium selected the only transfected cells. 18 days later, 
control cells died and bulk have been obtained. The raw data were analyzed putting in ratio 
the Firefly Luciferase with the Renilla Luciferase luminescence and the Graphic 1 shows 
that there is no difference between the relative luminescence value expressed after 24 
hours or after 18 days. 
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Graphic 1: Relative luminescence values after 24h and after 18 days in the bulk cells. 
The vector has the neomycin resistance sequence, so the cells were selected with the 
neomycin G-418 solution and we obtained several clones. At the end of selection, bulk 
cells were diluted to isolate clones. Then we analyzed the reporter gene (Firefly luciferase) 
both in the bulk and in clones (Graphic 2, Graphic 3). Comparing the bulk values, obtained 
from the two ratio (transposon : transposase), no significant differences in the Firefly 
luciferase expression have been identified; the relative luminescence values of the clones 
were similar between the two ratio 2:1 and 4:1, but the cellular viability was higher in the 
ratio 4:1, in fact it was easier to obtain a greater number of clones. 
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Graphic 2: Relative Luminescence values in HeLa bulks and clones. Top: transfection with transposon and 
transposase in 2:1 ratio. Bottom: transfection with transposon and transposase in 4:1 ratio. 
65 | P a g .  
 
B
u l
k
2 :
1  
1 C
2 :
1  
2 C
2 :
1  
2 D
2 :
1  
2 G
2 :
1  
3 E
2 :
1  
3 H
2 :
1  
4 D
2 :
1  
4 F
2 :
1  
4 H
2 :
1  
5 D
2 :
1  
6 C
2 :
1  
7 D
2 :
1  
7 F
2 :
1  
8 A
2 :
1  
9 G
2 :
1  
1 0
E
2 :
1  
1 2
F
2 :
1  
1 2
G
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
L u c ife r a s e  a s s a y :  C H O  c lo n e s  (2 :1 )
F
ir
e
fl
y
/R
e
n
il
la
 r
a
ti
o
0 ,4 3
0 ,4 8
1 ,6
1 ,0 9
0 ,5 1
0 ,2 8
0 ,3 8
0 ,3 6
0 ,6 5
0 ,3 9
0 ,2 2
0 ,5 3
0 ,3 8
0 ,2 4
0 ,5 7
0 ,3 7
0 ,3 6
0 ,3 3
0 ,2 7
 
B
u
lk
4 :
1  
6 F
4 :
1  
6 B
4 :
1  
9 E
4 :
1  
2 D
4 :
1  
6 B
4 :
1  
6 H
4 :
1  
1 C
4 :
1  
7 E
4 :
1  
3 A
4 :
1  
3 E
4 :
1  
7 D
4 :
1  
3 H
4 :
1  
7 H
4 :
1  
1 0
E
4 :
1  
6 F
4 :
1  
1 F
4 :
1  
1 0
H
4 :
1  
1 B
4 :
1  
8 B
4 :
1  
1 2
D
4 :
1  
1 1
A
4 :
1  
2 H
4 :
1  
1 2
A
4 :
1  
8 A
4 :
1  
1 1
E
4 :
1  
1 1
C
4 :
1  
3 E
4 :
1  
9 D
4 :
1  
5 H
4 :
1  
4 F
4 :
1  
5 B
4 :
1  
6 A
4 :
1  
6 D
4 :
1  
5 C
4 :
1  
4 G
0 .0
0 .5
1 .0
1 .5
L u c ife r a s e  a s s a y :  C H O  (4 :1 )
F
ir
e
fl
y
/R
e
n
il
la
 r
a
ti
o
0 ,43
0 ,37
0 ,55
0 ,95
0 ,27
0 ,49
0 ,18
0 ,58
0 ,53
0 ,2 8
0 ,31
0 ,41
0 ,29
0 ,37
0 ,43
0 ,13
0 ,45
0 ,43
0 ,2 7
0 ,65
0 ,31
0 ,6 8
0 ,2 8
0 ,2 1
0 ,33
0 ,16
0 ,3 0
0 ,3
0 ,27
0 ,6 1
0 ,3 6
0 ,3 9
0 ,3 2
0 ,26
0 ,4 2
0 ,29
 
Graphic 3: Relative Luminescence values in CHO bulks and clones. Top: transfection with transposon and 
transposase in 2:1 ratio; Bottom: transfection with transposon and transposase in 4:1 ratio. 
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Data suggest that the transgene expression is lasting in time. Comparing the two cell 
lines it is clear there is a variability, maybe due by the cellular molecules involved on the 
transposition mechanism. Moreover among the same cell line there is a difference between 
the clones, in particular some clones had a very high luciferase expression, such as the 
HeLa 12C clone (0.88) and CHO 2C (1.6), while others had very low expression values, 
for example HeLa 12H clone (0.0019) and CHO 6F clone (0.13). As it will be demonstrate 
in the following chapter, the transgene expression is not always correlated with the 
transposon copy number. 
5.1.3 Absolute Quantitative Real time PCR 
The absolute quantitative real time PCR was set up to establish the average transposon 
copy number in bulk and clone cells after the neomycin selection. 
We performed the calibration curve with the serial dilutions of the transposon plasmid 
using the primers which anneal on the right consensus sequence of transposase (IRDR_R). 
Another calibration curve was carried out using the dilutions of the plasmid containing the 
β-Globin sequence that allowed to normalize the data. The first calibration curve of 
transposon shows an efficiency of 100% and a regression of 0.999. The β-Globin standard 
curve shows an efficiency of 99,6% and a regression of 0.995. 
First of all we tested the DNA extracted from the bulk and three different clones of the 
HeLa and CHO cell lines. We have chosen the clones with high, mean and low value of 
Firefly luciferase luminescence in order to establish if there was a correlation between 
luminescence values and the transposon copy number. The Graphic 4 (Top) shows the 
transposon copy number in HeLa and CHO cell lines, and it is cleared that the CHO clones 
had a higher copy number of transgene integrated into the cellular genome, in particular 
the highest is the CHO 2G clone with approximately 26 copies. Data shows that there is a 
correlation between integrated copy numbers and relative luminescence values (Graphic 4) 
for the majority of the samples, except for the three samples colour in red where other 
elements should play a significant role in the reporter gene expression such as the 
integration site. 
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Graphic 4: Top: Transposon copy number in HeLa (grey) and CHO (pink) bulk and clones. Bottom: Relative 
luminescence values in HeLa (grey) and CHO (pink) bulk and clones. 
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To determine the efficiency of the “cut and paste” activity of transposase we set up an 
absolute real time PCR quantification (qPCR) to amplify a plasmid region located both in 
the episomal plasmids and in the excision circular plasmids (called PCR_2). Another 
absolute qPCR was performed to amplify the only episomal plasmids (called PCR_4). The 
efficiency of both reactions were of 98% and a regression of 0.999. Normalizing the data 
with the β-Globin amplification we measured the copy number of the total amount of 
plasmids inside the cells (PCR_2) and the copy number of the only episomal plasmids 
(PCR_4) and with a subtraction we calculated the copy number of the circle excision 
plasmid. In Graphic 5 is reported the ratio between the excision copy number and the total 
number of plasmids inside the cells (namely the data took from the PCR2). In this way it 
was possible to determine the efficiency of transposase activity expressed as percentage of 
the excision plasmid inside the cell after 48 hours from the transfection, that corresponds to 
the relative excision activity. Comparing the three cell lines there is no significant 
differences, even if the highest excision activity is on MO3.13 cell line.  
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Graphic 5: Relative Excision Activity. 
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The average transposon copy number was determined in the bulk cells of different cell 
types (SVG, Krabbe Fibroblast and MO3.13). The data, reported on the Graphic 6, show 
some differences between the various cell types highlighting that the transposition 
mechanism is influenced by the cell machinery [165]. On average the transposon copy 
number is not more than two. 
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Graphic 6: Average Transposon Copy Number. 
5.1.4 Relative quantitative Real Time PCR 
An important aspect essential to determine the in vitro gene therapy success, is the 
relative trans-gene expression. For this reason was performed a relative quantitative Real-
Time PCR using a serial dilution of the cDNA of each different bulk cell line. The raw data 
were analyzed applying the ΔΔCt method and normalized with the β-Actin gene 
expression. At the end we obtained the quantity change in the GALC expression (Graphic 
7). The treated Krabbe fibroblasts show an highly increase of GALC expression compared 
to the healthy control; in addition the difference between the same fibroblast before and 
after the transfection is highly significant with a p-value less than 0.0001. The SVG and 
MO3.13 cells show an increased expression higher of 1000-fold than untreated same 
cultures. 
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Graphic 7: Relative mRNA amount normalized to the b-actin gene expression. 
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5.1.5 Enzymatic activity 
To evaluate in vitro correction another essential aspect is to determine if translated 
exogenous protein is active. For this aim we have performed a specific enzymatic assay to 
measure the GALC activity. The proteins extracted from the bulk cells were used for the 
enzymatic test and we obtained two graphics that show the activity of the GALC enzyme 
(Graphic 8). Comparing the GALC activity in Krabbe fibroblasts before and after the 
transfection with the Sleeping Beauty system, as you would expect, the specific activity 
increase in the treated fibroblasts; in fact a p-value less than 0.0001 between treated and a 
untreated fibroblasts means that the difference has highly significance. While for the SVG 
and MO3.13 the difference between before and after the transfection has a mildly 
significance with a p-value less than 0.01. The increase in GALC activity is calculated by 
the ratio of the specific enzyme activity between the treated cells and the untreated control 
(Graphic 9). 
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Graphic 8: Specific enzymatic activity in Bulk cells expressed as nanomoles of substrate hydrolyzed per minute 
and normalized from milligram of protein. 
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Graphic 9: Increase in GALC activity. 
5.2 Plasmid labeling  
In order to follow the plasmid encapsulation preparation, each plasmid was covalently 
bound with a fluorescent tracker. During the preliminary test we labeled the pcGlobin2-
SB100Xco with the Label IT tracker TM-Rhodamine kit and the pT2HB-CAG-mGALC-
Ren/neo with the Label IT Tracker Fluorescein kit. 
To evaluate the covalent binding, the plasmids were run in an agarose gel (1%) without 
ethidium bromide staining. The nucleic acid appeared faint under UV illumination because 
the transilluminator emits at approximately 300 nm, which is not optimal for the 
fluorescent labels. Later the gel was stained with ethidium bromide to detect a potential gel 
shift related to unlabeled nucleic acids. Here, Figure 20 reports the example of the plasmid 
labeled with the Fluorescein tracker. Figure A shows the agarose gel without ethidium 
bromide staining, while the figure B shows the same gel stained with ethidium bromide; 
comparing the two gels it is easy to assume that the plasmid is covalently bind with the 
label. 
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Figure 20: Determination of labeling success. (A) Gel without ethidium bromide. (B) Gel with ethidium bromide 
staining. 1- plasmid without label; 2 and 3 plasmid labeled with Fluorescein 
To verify the presence of labeled DNA in vitro the MO3.13 cell line was transfected 
with 1.5 μg of pT2HB-CAG-mGALC-Ren/neo labeled with fluorescein and with 500 ng of 
pcGlobin2-SB100Xco labeled with rhodamine. The fixed cells were analyzed using 
fluorescent microscopy and the first image showed (Figure 21) the cells transfected with 
the transposon labeled with fluorescein (green), while the second (Figure 22) is showing 
the cells with the transposase labeled with rhodamine (red). In blue are displaying the 
nucleus (DAPI) and the cell membrane (Alexa Fluor 350 WGA). 
 
Figure 21: MO3.13 transfected with pT2HB-CAG-mGALC-Ren/neo labeled with fluorescein (green), stained with 
Alexa Fluor350 WGA (membrane, blue) and DAPI(nucleus, blue). Scale Bar indicates 35μm. 
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Figure 22: MO3.13 transfected with pcGlobin2-SB100Xco labeled with rhodamine (red), stained with Alexa 
Fluor350 WGA (membrane, blue) and DAPI (nucleus, blue). Scale Bar indicates 35μm. 
Analyzing these figures, the labeled plasmids have been uptaken by cells and it is 
possible to follow up their pathway into the cytoplasm. In fact the majority amount of the 
fluorescence was visible mainly inside the cytoplasm or around the nucleus membrane. 
5.3 g7 opioid peptide bound to PLGA nanoparticles  
Given that the aim is to transport the two plasmids across the Blood Brain Barrier, it 
was decided to establish the ability of the g7 peptide, bound to PLGA NPs, to get inside 
the mice brain. Unfortunately PLGA NPs are not suitable to encapsulate nuclei acids, 
maybe due to the inability of the hydrophobic PLGA to entrap hydrophilic DNA. PLGA 
NPs could be chemically modified to make them able to encapsulate nucleic acids, but 
these modifications change the physical-chemical properties, such as the dimension, the 
charge, the cellular toxicity and the cellular up-take. 
5.3.1 g7-PLGA nanoparticles preparation and characterization 
Both g7-NPs and DY-g7-NPS were characterized in their chemical, physical, and 
morphological features. The mean size of these NPs was close to 200 nm, the surface 
charge (z-p) was negative in all samples (–20/25 mV) with homogeneous distribution (PDI 
values lower than 0.04). The SEM analysis showed the spherical shape of the NPs (Figure 
23). These results clearly indicate that the modification with the g7 and DY did not affect 
the integrity and the superficial features of the NPs. 
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Figure 23: SEM image of DDY-g7-NPs. Scale Bar indicates 0.5μm. 
5.3.2 In vivo Imaging 
The in vivo imaging allowed us to detect the bio-distribution of DYg7-NPs in a bulb/C 
mouse after injection. The targeting of the probe to the brain area was monitored at 
different time intervals post-injection and normalized. We obtain overlapping images 
(Figure 24): the real image of the mouse that is viewed by the camera and the fluorescence 
image shown in a pseudo-colour scale representing the fluorescence intensity. 
 
Figure 24: Overlapping image the real image of the mouse that is viewed by the camera and the fluorescence 
image shown in a pseudo-colour scale representing the fluorescence intensity. 
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The prescan and after two hours fluorescence values in the control group are 
overlapping, in fact the p-value is 0.8, while the second group fluorescence values in the 
prescan and after two hours are significantly different (p value of 0.02) with a fluorescent 
increment of 12% (Graphic 10). 
 
Graphic 10:Average photon count. A- prescan of the control group; B- control group after 10 minutes from the 
injection of PLGA NPs without g7; C- control group after 22 hours from the injection of the PLGA NPs without 
g7; D- prescan of the treated group; E- fluorescence value after 10 minutes from the injection of PLGA NPs with 
g7; F- fluorescence value after 2 hours from the injection of PLGA NPs with g7. 
5.4 Chitosan nanoplexes and Chitosan/TPP-hyaluronic acid 
nanoparticles 
Chitosan polysaccharide has been chosen due to its ability to cross the cell membranes. 
This biodegradable and biocompatible polysaccharide is able to form nanoplexes with the 
plasmid DNA due to its cationic feature. As first experiments the simply chitosan 
nanoplexes were used to understand its ability to entrap the plasmid-DNA and its cellular 
up-take. Then, established the potential of chitosan as a good approach for the gene 
therapy, chitosan/TPP-hyaluronic acid nanoparticles were prepared in order to obtain more 
stable carrier with a higher up-take efficiency. Because of the enormous dimension of the 
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two plasmids, we started to evaluate the ability to entrap inside the chitosan matrix the 
smallest pcGlobin2-SB100Xco plasmid that is about 7000 bp. 
5.4.1 Preparation of chitosan/plasmid DNA nanoplexes 
Different preparations were obtained mixing the fixed amount of vectors with different 
concentrations of chitosan (Table 4). 
Preparation 
name 
Vector name μg of DNA 
μg 
of Chitosan 
Ratio 
Chitosan/DNA 
A 1 
pT2HB-CAG-mGALC-
Ren/neo 
38 7,6 1:5 
A 2 
pT2HB-CAG-mGALC-
Ren/neo 
38 38 1:1 
A 3 
pT2HB-CAG-mGALC-
Ren/neo 
38 190 5:1 
B 1 pcGlobin2-SB100Xco 61 12,2 1:5 
B 2 pcGlobin2-SB100Xco 61 61 1:1 
B 3 pcGlobin2-SB100Xco 61 305 5:1 
C 1 
pT2HB-CAG-mGALC-
Ren/neo+Rhodamine 
5 1 1:5 
C 2 
pT2HB-CAG-mGALC-
Ren/neo+Rhodamine 
5 5 1:1 
C 3 
pT2HB-CAG-mGALC-
Ren/neo+Rhodamine 
5 25 5:1 
D 1 
pcGlobin2-
SB100Xco+Fluoresceine 
5 1 1:5 
D 2 
pcGlobin2-
SB100Xco+Fluoresceine 
5 5 1:1 
D 3 
pcGlobin2-
SB100Xco+Fluoresceine 
5 25 5:1 
Table 4: Chitosan preparations. 
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5.4.2 Gel retardation assay of the chitosan nanoplexes 
The agarose gel electrophoresis was used to study the plasmid retardation caused by the 
polysaccharide. The Figure 25 shows that the migration of the nanoplexes is delayed in 
respect with the increasing amount of chitosan, so in the less negatively charged 
complexes. Comparing to the control naked plasmid, chitosan binding causes retarded 
mobility of the plasmid; in fact nanoplexes forming full complexation were retained within 
the well. In Figure 26 is shown the gel retardation assay after two weeks of storing at -
20°C, and the results demonstrate that the retardation is lightly maintained except for the 
sample D2 where the plasmid is released. 
 
Figure 25: agarose gel electrophoresis retardation assay of the chitosan-plasmid DNA at different 
chitosan/plasmid ratio. 1- naked plasmid of pT2HB-CAG-mGALC-Ren/neo; 2- naked plasmid of pcGlobin2-
SB100Xco. 
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Figure 26: agarose gel electrophoresis retardation assay of the chitosan-plasmid DNA at different 
chitosan/plasmid ratio after 13 days of storing at -20 °C. 1- naked plasmid of pT2HB-CAG-mGALC-Ren/neo; 2- 
naked plasmid of pcGlobin2-SB100Xco. 
5.4.3 Cell viability of the chitosan nanoplexes 
1.2x10^4 MO3.13 cells were plated on 96-well plate 24 hours before the viability assay. 
At 70% of confluence the cells were incubated for 2 hours with several concentrations of 
chitosan preparation (for the test were used the preparations CHIT2, CHIT3, CHIT4 that 
are made of only chitosan and A1, that is one of the nanoplex). After the incubation time 
has been performed the MTT assay (see above). Data were collected in triplicate. 
The cell viability was calculated using the following formula: 
Cell viability (%) = ( Abs sample/ Abs control) x 100 
The Graphic 11 shows the percentage of cellular viability after 4 hours of incubation 
with the MTT reagent. Clearly to an increase of chitosan concentration corresponds the 
decrease of cell viability, even if with a low significance p-value. 
81 | P a g .  
 
 
Graphic 11: Cell toxicity of chitosan and chitosan-plasmid DNA nanoplex on MO3.13 cell line. The data are 
represented as the mean ± standard deviation and were analyzed with the Student’s t-test. 
5.4.4 Cellular uptake of the chitosan nanoplexes 
The cellular uptake of the different chitosan preparations was performed using the 
MO3.13 cell line after tow and six hours of incubation. Looking at the different 
preparations it was clear that the increasing amount of chitosan promotes the cellular 
uptake. Comparing the preparation C3+D3 incubated for 2 hours and the same preparation 
incubated for six hours, it was noticeable that after six hours more number of cells showed 
a co-presence of the two plasmids. The Figure 27 shows a single cell, that after two hours 
of incubation time, has inside itself the both plasmids, while in Figure 28 are showing two 
examples of cells where there is co-localization of the two different fluorescent signal, in 
detail green and red dye that might be inside the nucleus and in the cytoplasm. 
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Figure 27: C3+D3: incubation of two hours: MO3.13 cell line treated with the two preparation of chitosan/plasmid 
DNA. In blue are the nucleus (DAPI) and the cellular membrane (Alexa350), in green pcGlobin2-SB100Xco 
plasmid and in red the pT2HB-CAG-mGALC-Ren/neo. Scale Bar indicates 35 μm. 
 
Figure 28: C3+D3 - incubation of six hours: MO3.13 cell line treated with the two preparation of chitosan/plasmid 
DNA. In blue are the nucleus (DAPI) and the cellular membrane (Alexa350), in green pcGlobin2-SB100Xco 
plasmid and in red the pT2HB-CAG-mGALC-Ren/neo. Scale Bar indicates 35 μm. 
5.4.5 Synthesis and characterization of Chitosan/TPP-hyaluronic acid 
nanoparticles 
pcGlobin2-SB100Xco-Fluorescein loaded nanoparticles were synthesized by the 
ionotropic gelation technique in presence of TPP, as described in the methodology section.  
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Particle size is known to affect the interaction and uptake of a nanomaterial at the 
cellular level. As shown in Figure 29, the size distribution of synthesized nanoparticle was 
found below 120.1 ± 11.2 nm with a narrow distribution. Determination of zeta potential 
was carried out to understand the charges as well as particle stability. Zeta potential for 
pcGlobin2-SB100Xco-Fluorescein loaded nanoparticles was found to be 29.7 ± 3.9 mV 
(Figure 30). Moreover, the encapsulation efficiency of synthesized nanoparticles was 42.3 
± 2.7 %. The nanoparticles formulated exhibit a strong positive charge on their surface, an 
important feature that not only influences particle–cell membrane interactions but also 
particle colloidal stability. 
 
Figure 29: Size distribution of pcGlobin2-SB100Xco+Fluorescein loaded nanoparticles (transposase/NPs). 
 
Figure 30: Surface charges of pcGlobin2-SB100Xco + Fluorescein loaded nanoparticles as determined by zeta 
potential. 
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5.4.6 Cellular uptake of the chitosan/TPP-hyaluronic acid nanoparticles 
The cellular uptake of the different chitosan preparations was performed using the A172 
cell line after 30 minutes, one hour and two hours and six hours of incubation. The 
incubation time influence the nanoparticles uptake; in Figure 31 are reported the cellular 
uptake after two hours of incubation with the pcGlobin2-SB100Xco+ Fluorescein, in detail 
the blue colour indicates cellular nucleus (DAPI staining) and the green colour indicates 
the fluorescence due to the labelled plasmid inside the cells. 
 
Figure 31: pcGlobin2-SB100Xco+ Fluorescein/NPs uptake in A172 cells. Left: cells with DAPI staining. Right: 
green fluorescence. Scale Bar indicates 200 μm. 
The relevance of incubation time in nanoparticles uptake was demonstrated measuring 
the percentage of nanoparticles uptaken per mg cell protein. As reported in Graphic 12 the 
uptake was seen as early as at 30 min, which increased gradually with the incubation time 
especially after two hours the uptake is significant. 
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Graphic 12: A172 uptake quantification of  pcGlobin2-SB100Xco+ Fluorescein after 30, 60 and 120 minutes. Mean 
± SD, n=3. 
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6 Discussion 
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Krabbe’s disease or Globoid cell Leukodystrophy is a fatal autosomal recessive 
lysosomal storage disorder caused by genetic or abnormalities of galactocerebrosidase 
gene that cause substrates accumulation in macrophages and neural tissue with a 
progressive loss of myelin [182]. And although the genetic cause of this disease was 
discovered many years ago, there is still no treatment. Currently the standard of care is the 
hematopoietic stem cell transplantation, even if it is effective only for slowly disease 
progression and only when initiated prior to symptom onset. Recently it has been 
considered more useful in clinical using a multimodality therapies. In recent years the gene 
therapy has been considered the most interesting approach to correct the GALC deficiency, 
in particular the virus-mediated (AAV) method is the widely used. Even if a relatively 
small number of cells can be transduced, this one can overexpress the GALC which can be 
secreted and correct adjacent cells [202]. In this work we have proposed a non-viral gene 
therapy approach in order to avoid the side effects caused by the viral methods, such as 
insertional mutagenesis. This new approach of gene therapy employs a Sleeping Beauty 
system [5]. It is composed of no viral elements (transposon and transposase) that use a “cut 
and paste” method that is safer than the viral methods. 
Given the involvement of the brain in the Krabbe’s Disease, we verify the ability of the 
synthetic opioid peptide (g7) to convey PLGA NPs inside the CNS [94]. This capability 
has been confirmed by our in vivo experiments. Unfortunately PLGA NPs are not suitable 
for the DNA binding due to their hydrophobicity. Moreover, one negative aspect of the 
transposon and the transposase are the plasmids’ sizes that make complicated their 
encapsulation. The PLGA NPs might be modified to make them more suitable for the 
nucleic acids binding, one of the most used molecule for this aim is the PEI, but this 
molecule increase the cells toxicity because high-MW PEI destroy membranous structures 
of cells and organelles, with lysosomal breakdown and mitochondrial damage. Moreover 
the PEI toxicity effect has negative impact on the cellular up-take [177, 178]. In addition 
during the preparation processes the DNA is exposed to several shear stress and organic 
solvents which could inactivate it. Also, most of the time, the nucleic acids are 
electrostatically bind on the external surface of the NPs causing problems of integrity 
[179]. 
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In order to encapsulate the plasmids we used chitosan NPs, a cationic polysaccharide. 
Some in vitro experiments have demonstrated the ability of the chitosan to entrap plasmids 
forming nanoplexes and their ability to enter inside the cells. The issue in using plasmid-
chitosan nanoplexes is their low stability in the blood stream, in fact they are usually use 
for local injection of miRNA to treat cancer [148]. To overcome the stability and poor 
solubility problems, the chitosan could be used to prepare more stable nanoparticles, such 
as the chitosan/TPP-hyaluronic acid NPs that we used to entrap the plasmids. From the 
preliminary in vitro experiments we obtained positive results that lead us to believe that 
chitosan/TPP-hyaluronic acid NPs are good carrier for the nucleic acids targeting. 
Moreover this type of nanoparticles could be modified in order to achieve the target site as 
it is reported in several works where the chitosan was modified to direct the carrier to the 
site of action [180, 212], so it could be linked with the opioid peptide g7 which is able to 
cross BBB and enter inside CNS.  
6.1 Plasmids modifications and in vitro transposase efficiency 
For the first functional study, we have chosen the vector with the luciferase gene that 
allows to perform either in vitro and in vivo experiments, in fact it is possible to measure 
the luciferase expression in cultured cells and also in vivo through the optical imaging 
technique [164]. Therefore we have required and obtained the Transposon with luciferase 
gene (pT2HB-CAG-Luc2) from Dott. Zsuzsanna Izsvàk (Max Delbück Center for 
Molecular Medicine, Berlin, Germany). To adapt this vector for our study, we modified the 
transposon inserting the Renilla luciferase and neomycin sequences. The Renilla luciferase 
bioluminescence has an important role in data normalization process; the ratio between 
Firefly and Renilla luciferase bioluminescence allows to evaluate the transfection 
efficiency. In addition, for the in vitro analysis, all cells with the transgene integration 
should be selected; this process it’s possible using the neomycin resistance inside the 
vector sequence. As second modification we amplified the GALC gene from a lentivirus 
vector and clone it inside the transposon instead of the firefly luciferase sequence. During 
the cloning process of the transposon we came across some issues related to the 
identification of enzymatic restriction sites and the length of the cloning fragment. 
Afterwards, all the interesting elements have been cloned inside the original transposon. 
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All the interesting sequences have been inserted between the two regions recognized by the 
transposase (inverted terminal repeat sequences, IR/DR (L) e IR/DR (R)).  
During the first part of this study, in order to evaluate the in vitro transposase efficiency 
we obtained and maintained in culture some clones of the two cell lines that we transfected 
with the two plasmids (the transposon pT2HB-CAG-Luc2-Ren/neo and the plasmid that 
codify for the transposase pcGlobin-SB100Xco). We were able to select the clones thanks 
to the presence of neomycin resistance sequence. First we analyzed the luciferase 
expression after 24 h in order to establish the best ratio to use between the transposon and 
the transposase. In accordance with literature, from the data we were able to identify that 
the cell transfected using the ratio 4:1 had higher level of luciferase expression than the 
ratio 2:1 (Graphic 1), moreover the cell viability was higher using the ratio 4:1 [213]. 
Moreover we analyzed the luciferase expression in the two cell lines after 30 days in the 
selected clones. The data confirm us that the expression is lasting in time, so the sleeping 
beauty system has an high transposition efficacy. Furthermore, some clones have higher 
level of luciferase expression than the bulk, indeed the bulk have value that is the average 
of the clones’ values. The Graphic 2 and Graphic 3 report the relative luminescence of 
some HeLa and CHO clones and they show differences between the two cell lines. 
Therefore the luciferase expression changes depending on evaluated cell line; this is in 
accord with literature where is reported that there is a correlation between the transposition 
efficiency and the cell type [30]. 
After the expression analyses, we designed the Real-time PCR in order to establish the 
reporter gene copy number. Progressively, from our data obtained from the bulk and 
clones’ DNA of the two cell lines with high, mean and low luminescence value have 
established a correlation between luminescence values and the transposon copy number, 
even if the expression could be influence by several factors. 
6.2 Relative excision efficiency 
Performing the gene therapy studies using the transposon elements, it is important to 
establish if the enzymatic element of this system (transposase) is able to work correctly in 
the model used in the experiments. For this reason some papers set up an approach to 
determine the excision activity using the absolute quantitative real time using the TaqMan 
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method [165, 166]. Here we used a different approach based on SyberGreen method and 
we were able to confirm that there was variation between the different cell line. We found 
that the major excision activity is in the MO3.13 cell line with an activity approximately of 
50%, while the less excision activity is in the primary cell culture of Human Fibroblast 
with an activity of 33%. This is in accord with literature because during the excision 
process are involved different cellular machinery, in addition the excision and transposition 
depends on the size of the transposed element. Moreover the excision activity is not strictly 
correlated with the copies that are transpose in the cellular genome, and our data confirmed 
the absence of correlation between the two events (the excision and the transposition) [30]. 
6.3 Sleeping Beauty system efficacy 
Defined that the sleeping beauty system works well in our models and our vectors 
didn’t have any modification that could influence the transposition, we focused on the 
analysis of the sleeping beauty system efficacy in the cell line that are closing to our final 
target. We took in exam the SVG cell line (fetal human astrocyte cell line), the human 
fibroblast and the MO3.13 cell line (human oligodendrocyte cell line). For these cell lines 
we evaluate the transposon copy number, the mRNA expression and the enzymatic activity 
after the bulk selection. Referring to the results obtained from the analysis of the cells after 
the transfection, it was clear a correlation between the transposon copy number, the GALC 
expression and the enzymatic activity (Graphic 6, Graphic 7, Graphic 8). The transposon 
copy number is not more than two copies in each cell, this is important when you 
considered the gene therapy application, because low transgene copy number means a low 
risk of insertional mutagenesis [30]. Moreover, it is interesting to see the efficacy of this 
system evaluating the increment on the enzymatic activity (Graphic 9) that is the final goal 
of the gene therapy, in particular the human Krabbe fibroblasts have an increment of fifty-
five fold in GALC activity. 
6.4 The ability of g7 opioid peptide to cross the Blood Brain Barrier 
The substantial involvement of the Central Nervous System in Krabbe’s disease had led 
us to plan a strategy able to help the NPs to cross the Blood Brain Barrier (BBB). In fact 
we have evaluated if the synthetic opioid peptide was the right strategy to achieve our goal. 
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6.4.1 g7 bound to PLGA nanoparticles synthesis and characterization 
The characterization of the PLGA NPs features conformed the size, the good 
homogeneity and the surface charges is compatible with the systemic administration. 
Moreover the nanoparticles features were not affected by the covalent modification with 
the g7 peptide. 
6.4.2 In vivo imaging 
We analyze the bio-distribution of the g7 peptide bound on PLGA-NPs surface, even if 
this kind of polymer is not suitable to bind and release nucleic acids. 
After intravenous injection, the NPs are widely distributed in the animal organs (data 
not shown), mainly in lungs, liver and spleen. This distribution confirm that the NPs are 
rapidly up-taken by the reticuloendothelial system (RES) [121, 122]. 
These data show that the opioid peptide localized inside the central nervous system and 
also after two hours the fluorescence signal increase of 12% in the mice injected with NPs 
coated with g7 compared to the mice injected with NPs without g7. 
6.5 Chitosan polysaccharide as gene delivery 
Chitosan shows several characteristics that makes it suitable as gene delivery system, 
especially because it is able to form complexes with negatively charged plasmid DNA, 
RNA, siRNA and miRNA due to its cationic nature [214]. However the chemical 
modification are required to change its physicochemical and pharmacological properties in 
order to increase its solubility [215]. At the beginning, it was studied the ability of the 
simple chitosan nanoplexes to entrap and target the plasmid-DNA inside the cellular model 
(MO3.13 cell line). So, confirmed the possibility to use this polysaccharide as carrier, it 
was modified to make it more stable and less toxic. In order to achieve this aim, during the 
preparation processes was added the crosslinker TPP, which increase the stability of the 
nanoparticles, and the hyaluronic acid that made this NPs less degradable in blood stream 
and less toxic [167]. As it is reported in literature, the chitosan/TPP-hyaluronic acid is 
suitable nanoparticle for the gene therapy because the chitosan is able to create complexes 
with the negative charges of the DNA. Moreover the chitosan could be functionalized on 
its surface with molecules in order to target the cargo in a specific site, in particular several 
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works have already used chitosan nanoparticles functionalized on their surface with 
antibodies in order to target drugs into solid tumors or into the brain [168, 169]. In fact we 
want to bind the synthetic opioid peptide (g7) on the chitosan/TPP-hyaluronic acid NPs 
surface to direct the NPs into the CNS. 
6.5.1 Nanoplexes preparation, cellular up-take and cytotoxicity  
In this study the nanoplexes formulation has been prepared by simple self-assembled 
electrostatic complexation by mixing in aqueous solution the low molecular weight 
chitosan at different ratio of plasmid. The complexation and the stability was controlled 
evaluating the agarose gel electrophoresis retardation, that demonstrate a relation between 
the amount of the chitosan and the binding efficiency of the plasmid, in addition this assay 
highlights that the nanoplexes are quite stable if they are stored in aqueous solution at -20 
°C, this is maybe because the high level of DA (87%) make the complex more stable. 
In vitro study was performed to control the cellular uptake and the cellular 
internalization of the nanoplexes. After two and six hours the nanoplexes are taken up, 
after two hours the internalization was not widely distributed in all cells, in fact only few 
cells have shown a co-presence of the both plasmid; while after six hours of incubation the 
fluorescence was widely distributed inside the cells and a major number of cells showed 
the co-presence of the two fluorescence labels. 
Form this preliminary tests, chitosan results to be suitable for biomedical application 
because it is biocompatible and induce low cytotoxicity [157], in fact our results suggest 
that cell viability remain high and at higher chitosan concentration the differences with the 
untreated control is lightly significant. 
6.5.2 Chitosan/TPP-hyaluronic acid nanoparticles synthesis and 
characterization 
In agreement with literature, our results confirmed that the ionotropic gelation technique 
is a good method to obtain chitosan/TPP-hyaluronic acid nanoparticles [175]. 
One of the most important parameter that influenced the cellular uptake is the 
nanoparticles size that is also connected with the size of the plasmid. Despite the 
outstanding dimension of the pcGlobin2-SB100Xco plasmid, we were able to entrap it 
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inside the chitosan/TPP-hyaluronic acid nanoparticles maintaining a small nanoparticles 
dimension. 
During the cellular up-take, another important parameter is the surface charges, 
especially for the endo-lysosomes escape, in fact recent works claimed that positive charge 
nanoparticles are able to bind anionic microtubules or molecular motor proteins and move 
towards the nucleus by the cytoskeletal network [216]. The positive charge of our 
nanoparticles suggests that they are able to bind the cell membrane and favor the cellular 
uptake. 
Even if the enormous dimension of our plasmids has caused problems in the 
encapsulation process, we obtained a good encapsulation efficiency of the pcGlobin2-
SB100Xco plasmid inside the chitosan/TPP hyaluronic acid nanoparticles (42.3 ± 2.7 %). 
6.5.3 Chitosan/TPP-hyaluronic acid nanoparticles cellular uptake 
In vitro preliminary test has demonstrated that chitosan/TPP hyaluronic acid 
nanoparticles with the pcGlobin2-SB100Xco+Fluorescein are able to enter inside the cells. 
Of course the uptake increase proportionally with the increasing of incubation time, in fact 
after one hour the uptake efficiency is more than 50%. Moreover the green fluorescence 
inside the nucleus demonstrate the ability of the hyaluronic acid to pass the 
membrane[217]. What is lacking is the evidence that the plasmid is released inside the 
cells and it is able to produce an active protein. 
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7 Conclusion 
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Krabbe’s disease is a rare genetic disorder with lack of a definitive and efficient therapy 
because of the CNS involvement. In fact the big problem is to get to the brain and cross the 
blood brain barrier, for this reason among the gene therapies the most effective one is the 
AAV method because the capsid protein shows an high tropism, in particular the serotype 
AAArh10 is able to cross the blood brain barrier. The problems related to the use of virus 
on gene therapy have led us to followed the direction of the non-viral gene therapy, in 
particular the use of a method called “Sleeping Beauty”. The peculiarity of this system is 
that the transgene is translocated on the cellular genome by a “cut and paste” method that 
avoid to insert mutations, in addition the fairly random integration guarantees the tendency 
to integrate inside introns. 
During the molecular experiments, we came upon several difficulties during the 
transposon plasmid modification. The original pT2HB-CAG-Luc2 (transposon) was 
modified twice, the first modification was made in order to analyze in vitro the reporter 
gene expression and the second one was made in order to obtain the final plasmid that 
codified for the cDNA of the GALC gene. Moreover in order to study the efficiency of the 
Sleeping Beauty System we designed several molecular assays. Two absolute quantitative 
real time (SyberGreen method) were performed to establish the excision activity after 48 
hours from transfection, that allows us to evaluate the efficiency of the transposase in 
different cell types, and the other one was performed to analyze the transposon copy 
number to establish the correlation between excision activity, translocation event and gene 
expression. In order to assay the transgene expression were performed two different 
analysis, a relative quantitative real time (ΔΔCt method) was set up to understand the 
expression of the GALC mRNA; and a specific enzymatic assay was done to evaluate if 
there was a real effect at protein level with an increment on the GALC activity. Our data, 
obtained analyzing different cellular models, show an high efficiency of the SB system and 
the differences between samples confirmed that every cell types have different molecular 
mechanisms that interact with the SB system and the transposition mechanism. Moreover 
we established that the modified transposon (pT2HB-CAG-mGALC-Ren/neo) was able to 
increase the GALC activity in our cellular models. 
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Because of the main organ involved on Krabbe’s disease is the brain and given that the 
naked plasmid DNA is totally unable to cross the BBB, we tried to target the plasmids 
through the use of nanoparticles. 
To achieve the brain we verify the ability of the g7 peptide to cross the blood brain 
barrier and our in vivo experiments confirmed the ability of the synthetic opioid peptide g7 
bound to PLGA NPs to cross the BBB. Unfortunately this type of NPs are not suitable for 
the encapsulation and release of nucleic acids, for this reason we do not used this polymer 
as carrier to target our plasmids. 
In order to protect the plasmid against degradation we entrapped them inside the matrix 
of the polysaccharide chitosan. Chitosan is the most widely used polysaccharide for the 
gene therapy. Our results suggest that the simple chitosan nanoplexes are able to drag 
plasmid DNA inside the cells, in spite of the big plasmids dimension. Successively more 
stable chitosan/TPP-hyaluronic acid nanoparticles were prepared to entrap the two 
plasmids inside the chitosan matrix. Preliminary in vitro test suggests that this type of 
nanoparticles have a big potential as plasmid-DNA delivery. 
Next steps will be to encapsulate with an high efficiency the transposon inside the 
matrix of the chitosan/TPP-hyaluronic acid nanoparticles, overcoming the problems due to 
its dimension. Then, this nanoparticles will be modified conjugating the synthetic opioid 
peptide g7. Subsequently, we will study the efficiency of this system in vitro evaluating in 
our cellular model the excision activity, the transposon copy number, the expression and 
the activity of the recombinant GALC protein. So, if we have good results from the in vitro 
tests, we will evaluate this system in mice model. First, the in vivo toxicity and bio-
distribution will be studied in control mice (such as Balb/c mice) to understand the 
injectable amount of nanoparticles and the best way of administration. Then the efficiency 
of the Sleeping Beauty will be tested in vivo using the Twitcher mouse, the animal model 
of the Krabbe’s disease. 
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